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9ABSTRACT
BACKROUND Severe sepsis is associated with common occurrence, high costs of care
and significant mortality. The incidence of severe sepsis has been reported to vary between
0.5/1000 and 3/1000 in different studies. The worldwide Severe Sepsis Campaign,
guidelines and treatment protocols aim at decreasing severe sepsis associated high
morbidity and mortality. Various mediators of inflammation, such as high mobility group
box-1 protein (HMGB1) and vascular endothelial growth factor (VEGF), have been tested
for severity of illness and outcome in severe sepsis. Long-term survival with quality of life
(QOL)  assessment  is  important  outcome  after  severe  sepsis.  The  objective  of  this  study
was to evaluate the incidence, severity of organ dysfunction and outcome of severe sepsis
in intensive care treated patients in Finland. HMGB1 and VEGF were studied in predicting
severity of illness, development and type of organ dysfunction and hospital mortality. The
long-term outcome and quality of life were assessed and quality-adjusted life years and
cost per one QALY were estimated.
PATIENTS A total of 470 patients with severe sepsis were included in the study. Patients
were treated in 24 Finnish intensive care units in a 4-month period from 1 November 2004
to 28 February 2005.
MAIN RESULTS The incidence of severe sepsis was 0.38 /1,000 in the adult population
(95% confidence interval 0.34-0.41). Septic shock (77%), severe oxygenation impairment
(71.4%) and acute renal failure (23.2%) were the most common organ failures. The ICU,
hospital, one-year and two-year mortalities were 15.5%, 28.3%, 40.9% and 44.9%
respectively. HMGB1 and VEGF were elevated in patients with severe sepsis. VEGF
concentrations were lower in non-survivors than in survivors, but HMGB1 levels did not
differ between patients. Neither HMGB1 nor VEGF were predictive of hospital mortality.
The QOL was measured median 17 months after severe sepsis and QOL was lower than in
reference population. The mean QALY was 15.2 years for a surviving patient and the cost
for one QALY was 2,139 €.
CONCLUSIONS This study showed that the incidence of severe sepsis is lower in
Finland than in other countries. The short-term outcome is comparable with that in other
countries, but long-term outcome is poor. HMGB1 and VEGF are not useful in predicting
mortality in severe sepsis. The mean QALY for a surviving patient is 15.2 and as the cost
for one QALY is reasonably low, the intensive care is cost-effective in patients with severe
sepsis.
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1 INTRODUCTION
Severe sepsis has long been a challenge in intensive care because of its common
occurrence and the high costs of care. Severe sepsis is associated with significant
mortality, which has varied between 27% and 55% in different studies (Flaatten 2004;
Engel et al. 2007). The incidence or outcome of severe sepsis has not been prospectively
studied in the Nordic countries. The incidence of severe sepsis increases annually 1.5%
mainly due to the ageing population (Angus et al. 2001 a). Some studies have shown that
the prognosis of severe sepsis can be improved (Rivers et al. 2001; Bernard et al. 2001).
The international Surviving Sepsis Campaign (SSC) first published guidelines for severe
sepsis in 2004 (Dellinger et al. 2004) and an update in 2008 (Dellinger et al. 2008). The
main objective of SSC is to decrease mortality by 25% in five years.
The  SSC  guidelines  for  severe  sepsis  treatment  are  based  on  studies  showing  that  with
relatively simple therapeutic interventions it is possible to save a significant number of
lives. Treatments such as ventilation with low tidal volumes (The Acute Respiratory
Distress Syndrome Network 2000), low-dose hydrocortisone for vasopressor-resistant
septic shock (Annane et al. 2002) and recombinant human activated protein C (rhAPC)
(Bernard et al. 2001) have been selected as recommended treatments in the Campaign's
Sepsis Management Bundle. Administration of antimicrobial treatment within 3 hours
after diagnosis of severe sepsis is recommended (Dellinger et al. 2008). In fact, hospital
survival increases if adequate antimicrobial treatment is started within one hour after
documented hypotension in septic shock (Kumar et al. 2006). However, recent studies
concerning lung protective ventilation have shown that the compliance with the new
guidelines into practice is also inadequate in a critical care setting (Young et al. 2004;
Kalhan et al. 2006).
Numerous studies have emphasized the important role of proinflammatory cytokines in
sepsis. Despite their obvious role in the pathogenesis of severe sepsis, attempts to improve
the prognosis of sepsis by inhibiting ‘early’ cytokine-mediated inflammatory process have
failed (Opal et al. 1997; Abraham et al. 1998). Since then, novel mediators of severe sepsis
as high mobility group box-1 protein (HMGB1) have emerged (Wang et al. 1999). It is
speculated that it might be a potential target for anti-inflammatory treatments (Yang et al.
2004). Vascular permeability increases in response to systemic inflammation mediated by
11
endotoxin and various cytokines. Macrophages and lymphocytes produce vascular
endothelial growth factor (VEGF), which is a potent endogenous mediator of vascular
permeability (Senger et al. 1983). In addition, VEGF is a potent hypoxia-induced mediator
of angiogenesis (Shweiki et al. 1992).
Short-term mortality such as 28-day or 2-month mortality has been used to measure
outcome in sepsis studies (Bernard et al. 2001; Rivers et al. 2001; Sprung et al. 2008).
Severe sepsis often causes several organ dysfunctions, from which surviving patients may
recover slowly. Long-term outcome has been determined in only few studies and one-year
mortality has been 51.4% and five-year mortality as high as 74.2% after severe sepsis
(Weycker et al. 2003). Nowadays, short-term survival is not the only adequate outcome
and long-term survival and quality of life (QOL) have also become an important outcome
(Marshall et al. 2005). Poor quality of life before intensive care admission may even
predict poor outcome (Hofhuis et al. 2007).
A quality-adjusted life year (QALY) comprises length of life and quality of life. The
concept of QALY enables comparisons of the efficacies of different treatments and
calculations of costs per QALY. Cost-effectiveness analysis measures benefits of
treatments in terms of life years saved. Cost-utility analysis measures treatments using
number of QALYs as a unit of efficacy (Anonymous 2002). In intensive care medicine, the
generally accepted cost for one life year gained or for one QALY has been $50,000
(Talmor et al. 2006).
In this nationwide study the aim was to investigate the incidence of severe sepsis,
associated organ dysfunction and outcome. HMGB-1 and VEGF as mediators of
inflammation were studied in the prediction of severity of organ dysfunction and hospital
mortality. Special attention was paid to long-term survival and quality of life before and
after severe sepsis. As severe sepsis is often associated with high cost of treatment, the
quality-adjusted  life  years  were  estimated  for  survivors  and  cost  of  treatment  was
calculated.
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2 REVIEW OF THE LITERATURE
2.1 DEFINITION OF SEVERE SEPSIS
Sepsis is defined as a host's systemic response to infection (Ayres 1985). Different terms
such as septicaemia, sepsis or sepsis syndrome were used without precise definitions or
even in inflammatory states without infection (Bihari 1990; Marshall et al. 1990). The
most widely used definitions of sepsis, severe sepsis and septic shock were published in
1992 by the Consensus Conference of the American College of Chest Physicians (ACCP)
and  Society  of  Critical  Care  Medicine  (SCCM)  (Bone  et  al.  1992).  The  systemic
inflammatory response syndrome (SIRS) was introduced to represent the body's systemic
response to infection. SIRS criteria consist of changes in temperature, heart rate,
respiratory rate or leucocyte count (Table 1).
Table 1. The SIRS criteria (Bone et al. 1992).
> 2 of the following conditions
· Temperature > 38 ºC or < 36 ºC
· Heart rate > 90 beats per minute
· Respiratory rate > 20 breaths per minute or pCO2 < 32 mmHg (4.3 kPa)
· White blood cell count > 12 x 109/l or < 4 x 109/l or > 10% immature (band) forms
A microbiologically proven or suspected infection together with SIRS is defined as sepsis.
Severe sepsis is sepsis with acute organ dysfunction, hypoperfusion or sepsis-induced
hypotension (systolic blood pressure < 90 mmHg or a reduction > 40 mmHg from
baseline).  Septic  shock  is  defined  as  severe  sepsis  with  hypotension  that  persists  despite
adequate fluid resuscitation or with signs of hypoperfusion (e.g. lactic acidosis or oliguria)
in patients with vasoactive treatment. These broad definitions were suitable for clinicians
at the bedside to diagnose severe sepsis, but more precise definitions were required,
especially for inclusion in clinical trials (Levy et al. 2003). The relationship between
infection, SIRS and severe sepsis is presented in Figure 1.
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3.Sepsis=1+2
5.Severe sepsis=3+4
(septic shock)
2.SIRS
1. Infection
4.Organ failure+
+
Figure 1. Relation of infection, SIRS, sepsis and severe sepsis.
2.1.1 Systemic inflammatory response syndrome
Systemic inflammatory response can result from trauma, burns, postoperative states,
pancreatitis or autoimmune diseases without proven infection. SIRS criteria were criticized
as being too insensitive and unspecific and having no prognostic value. Rangel-Frausto in
1995 published the first study on the epidemiology of  SIRS and  its  continuum to  sepsis,
severe sepsis and septic shock (Rangel-Frausto et al. 1995). Over 3,500 patients were
screened for SIRS in three ICUs and general wards and 68% of the patients met >2 SIRS
criteria. SIRS was related to confirmed infection only in 50% of patients as SIRS-positive
patients were found to have sepsis in 26%, severe sepsis in 18% and septic shock in 4% of
cases. In that study, 28-day mortality varied from 7% in patients with SIRS to 46% in
patients with septic shock. Patients with infection at admission or during the ICU stay were
studied in the European Sepsis Study five years later (Alberti et al. 2002). The mortality
varied from 20% to 60% in different sepsis categories, but did not differ between patients
with infection and with or without SIRS. Mortality was unaffected by the number of SIRS
criteria fulfilled (Alberti et al. 2003). Despite the nonspecificity of SIRS criteria, they have
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maintained their position as a marker of systemic inflammatory response (Levy et al.
2003).
2.1.2 Organ dysfunction
Existing organ dysfunction or failure is essential for the diagnosis of severe sepsis, but they
are not precisely defined in the Consensus criteria (Bone et al. 1992). Sepsis trials have
used organ dysfunction definitions of their own (Warren et al. 2001; Brunkhorst et al.
2008) and organ failure criteria used in the Prowess trial (Bernard et al. 2001) have been
adapted for other studies as well (Finfer et al. 2004 a; Abraham et al. 2005). The most
widely used score for the assessment of organ dysfunction was developed by the working
group on sepsis-related problems of the European Society of Intensive Care Medicine 1994
and published 2 years later as the Sepsis-related Organ Failure Assessment (SOFA) score
(Vincent et al. 1996). Soon this "sepsis-relation" was renamed "sequential", because these
types of organ dysfunctions are not only related to infection. Organ function is graded from
0-4 points (from 0=no dysfunction to 4=severe dysfunction) in six different organ systems
(Table 2).
Table 2. The SOFA score.
Organ
dysfunction
0 point 1 point 2 points 3 points 4 points
Respiration
Pa O2/ FiO2
> 400 mmHg
(> 53.3 kPa)
< 400 mmHg
(< 53.3 kPa)
< 300 mmHg
(< 40 kPa)
< 200 mmHg
(< 26.7 kPa)
with respiratory
support
< 100 mmHg
(< 13.3 kPa)
with respiratory
support
Cardiovascular
MAP or
vasoactive
treatment
MAP > 70
mmHg
MAP < 70
mmHg
Dopamine
< 5 ?g/kg/min
or dobutamine
any dose
Dopamine
> 5 ?g/kg/min or
norepinephrine
or epinephrine
< 0.1 ?g/kg/min
Dopamine
> 15 ?g/kg/min or
norepinephrine
or epinephrine
> 0.1 ?g/kg/min
Renal
Creatinine
or diuresis/24h
< 110
?mol/l
110-170
?mol/l
171-299
?mol/l
300-440 ?mol/l
or diuresis
< 500ml/24 h
>440 ?mol/l
or diuresis
< 200ml/24 h
Coagulation
Tromb
> 150 x 109/l < 150 x 109/l < 100 x 109/l < 50 10x 109/l < 20 x 109/l
Liver
Bilirubin
< 20
?mol/l
20-32
?mol/l
33-101
?mol/l
102-204
?mol/l
> 204
?mol/l
Central nervous
System (GCS)
15 13-14 10-12 6-9 < 6
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Increasing or constantly high SOFA scores are correlated with morbidity and mortality in
patients with severe sepsis (Levy et al. 2005), ICU patients in general (Vincent et al. 1998;
Moreno et al. 1999), as well as in patients with trauma (Antonelli et al. 1999). There are
other organ dysfunction scores, e.g. the multiple organ dysfunction score (MODS), which
was introduced one year before SOFA (Marshall et al. 1995). MODS has been shown to
correlate with mortality (Jacobs et al. 1999). MODS includes the same six organ systems
as SOFA but cardiovascular dysfunction is more complicated to score. Unfortunately, both
scoring systems lack gastrointestinal dysfunction, because no suitable descriptor for that
organ system was agreed (Marshall et al. 1995). The MODS score is not widely used.
Sepsis definitions were re-evaluated in 2001 but were left practically unchanged (Levy et
al.  2003).  Additional  diagnostic  criteria  for  sepsis  were  proposed,  but  none  of  them  was
specific for sepsis. However, a new concept for staging sepsis was introduced based on a
TNM-classification system in oncology (Denoix 1946). This new system was first called
IRO, where I stands for insult (infection), R for response (SIRS, other signs of sepsis) and
O  for  organ  dysfunction  (SOFA,  MODS)  (Marshall  et  al.  2003).  After  P  was  added  for
predisposition (premorbid illness), the concept is called PIRO (Levy et al. 2003). This new
PIRO  system  was  left  at  the  conceptual  level  until  the  first  large  study  to  use  the  PIRO
concept for outcome prediction was published 4 years after this concept was introduced
(Moreno et al. 2008). Modified PIRO (organ failure included in response) was tested in
SAPS 3 study in patients with infection or sepsis. The SAPS 3 PIRO score was introduced
with the ability to predict hospital mortality accurately in patients with infection, sepsis or
severe sepsis (Metnitz et al. 2005).
2.1.3 Infection
The ACCP/SCCM consensus presented a broad definition for infection as an invasion of
normally sterile tissues by microorganisms or as an inflammatory response they cause
(Bone et al. 1992). Bacteraemia (correspondingly viraemia, fungaemia or parasitaemia) is
defined as a type of infection with viable micro organisms in the blood. Bloodstream
infection (BSI) with a positive blood culture is not needed for a diagnosis of sepsis. When
over 1,900 ICU patients were evaluated, 92% of them had SIRS, 6% had sepsis with BSI
and 3% septic shock with BSI (Laupland et al. 2004). In fact, positive blood cultures are
detected in only 20%-55% in patients with severe sepsis or septic shock (Brun-Buisson et
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al. 1995; Alberti et al. 2002; Vallés et al. 2003; Ylipalosaari et al. 2006). Abdominal
infections are more likely to be associated with positive blood cultures than other foci
(Alberti et al. 2002). Infections causing severe sepsis can be microbiologically documented
in only 32.5%-71% of cases (Brun-Buisson et al. 1995; Vincent et al. 2006; Moreno et al.
2008, Engel et al. 2007). Hospital-acquired infections are more often microbiologically
confirmed (71% vs. 55%) than community-acquired infections (Alberti et al. 2002).
The broad infection definitions were used in many interventional clinical trials that were
unsuccessful in demonstrating benefit from experimental drugs in severe sepsis like anti-
tumour necrosis factor (anti-TNF) monoclonal antibody trial (Fisher et al. 1993), anti-
platelet activating factor (PAF) receptor antagonist trial (Dhainaut et al. 1998) or high dose
antithrombin (AT) III trial (Warren et al. 2001). The rhAPC trial with positive results (the
Prowess Study) also used modified Consensus criteria (Bernard et al. 2001). However, the
heterogeneity of treatment groups in previous trials was suspected to be one reason for the
unexpected results. Precise definitions of infection in ICU treated patients with severe
sepsis were needed to improve the quality and comparability of clinical trials.
A consensus conference was held in 2003 and the definitions of infection in the intensive
care unit were published in 2005 (Calandra et al. 2005). The six most common infection
types were identified and described with precise definitions such as pneumonia,
bloodstream infections (including infective endocarditis), intravascular catheter-related
sepsis, intra-abdominal infections, urosepsis, and skin and soft tissue infections (surgical
wound infections or nonsurgical site infections). In addition, each type of infection was
classified as being microbiologically confirmed, probable or possible. Large clinical trials
or epidemiological studies in severe sepsis published in recent years have not yet been able
to use these detailed definitions of infection because patient recruitments have started
before 2005. (Abraham et al. 2005; Vincent et al. 2006; Sprung et al. 2008; Brunkhorst et
al. 2008). Most recent epidemiological studies have used the old or modified Consensus
criteria for infection (Cheng et al. 2007; Engel et al. 2007).
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2.2 INCIDENCE OF SEVERE SEPSIS
2.2.1 Incidence
The first study to show the high incidence of severe sepsis on population level was
published at the beginning of this millennium (Angus et al. 2001 a). This large
retrospective study screened the data of over 6.6 million hospital discharge records in USA
and over 192,000 patients with severe sepsis were identified. The estimated incidence of
severe sepsis was 3/1,000 population in 1995, which meant 751,000 patients annually in
USA. Half of those patients were treated in intensive care. Another large retrospective
study found similar incidence of 2.4/1,000 ten years later (Martin et al. 2003). The
incidence was lower in prospective studies with limited study population as in patients
treated in ICU. These estimations have varied between 0.51/1,000 and 0.77/1,000 in adult
populations (Padkin et al. 2003; Finfer et al. 2004 a). The proportion of patients with
severe sepsis in ICU admissions has varied from 9% to 27% (Brun-Buisson et al. 1995.
Padkin et al. 2003), but has been around 10%-12% in most studies (Sands et al. 1997;
Finfer et al. 2004 a; van Gestel et al. 2004; Engel et al. 2007). In the European SOAP study
a notable difference was found on ICU admissions between different countries.
Switzerland had the lowest (10%) and Portugal the highest (64%) severe sepsis rates on
ICU admission (Vincent et  al.  2006).  Assuming that only half  of the patients with severe
sepsis are treated in ICUs, prospective studies still have clearly lower incidence numbers
than retrospective studies. However, since most prospective incidence studies have been
conducted in ICU-treated patients, the incidence numbers may reflect more ICU beds
available for treating severe sepsis than true incidence in population (Linde-Zwirble et al.
2004). The data on sepsis or severe sepsis incidence studies are presented in Table 3.
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Table 3. Incidence of severe sepsis in different studies. Adm=admission, NA=not
applicable.
Reference Country Time frame
and design
Severe
sepsis
definition
No. of
patients
screened
Screened
population
No. of
patients
Incidence Age
(years)
Male
Salvo et
al. 1995
Italy 01.04.1993-
31.03.1994
Prospective
Consensus
criteria
(1992)
1,101 All patients
in 99 ICUs
128 NA NA
Rangel-
Frausto et
al. 1995
USA 01.08.1992-
30.04.1993
Prospective
Consensus
Criteria
(1992)
3,708 All adult
(>16 yr)
patients
with SIRS
in 3 ICUs
and wards
467 culture
positive
527 culture
negative
NA Mean 55
Male 60%
All
patients
with SIRS
Brun-
Buisson et
al. 1995
France 04.01.1993-
28.02.1993
Prospective
Consensus
Criteria +
criteria for
organ
failure
11,828 All adult
ICU adm
170 ICUs
1,052
patients
1,064
septic
episodes
NA Mean 61
Male 63%
Sands et
al. 1997
USA 04.01.1993-
02.04.1994
Prospective
Consensus
criteria
(1992)
12,759 All adm in
ICU, all
blood
culture-
positive in
8 hospitals
1,166
patients
1,342
septic
episodes
2.8/1,000
patient
days
Mean 59
Male 56%
Angus et
al. 2001 a
USA 1995
Retrospective
ICD-9 6,621,559 Hospital
discharge
data, all
ages
192,980 3/1,000
population
Mean 59
Male 53%
Alberti et
al. 2002
8 European
countries,
Canada and
Israel
01.05.1997-
31.05.1998
Prospective
Consensus
Criteria+
organ
failure
criteria
14,364 All adult
(>18 yr) in
28 ICUs
8,353 (LOS
ICU >24 h
)
NA NA
Martin et
al. 2003
USA 1979-2000
Retrospective
ICD-9 750,000,000 Hospital
discharge
data,
all ages
10,319,418
patients
with sepsis
(16.6%-
33.6%)
0.83/1,000
2.4/1,000
population
Mean 57-
61
Male
50%-48%
Padkin et
al. 2003
England,
Wales and
Northern
Ireland
01.12.1995-
28.02.2000
Retrospective
Prowess
criteria
56,673 All adult
(>16 yr)
adm first
24h in 91
ICUs
15,362 0.51/1,000
population
Median 65
Male 54%
Flaatten
2004
Norway 01.01.1999-
31.12.1999
Retrospective
ICD-10 700,107 All hospital
patients in
1 year
2,121 1.49/1,000
3/1,000
hospital
admission
Mean 58
Male 52%
(sepsis)
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Table 3. Incidence of severe sepsis in different studies. Adm=admission, NA=not
applicable.
Reference Country Time frame
and design
Severe
sepsis
definition
No. of
patients
screened
Screened
population
No. of
patients
(%)
Incidence Age
(years)
Male
Finfer et
al. 2004
Australia 01.05.1999-
31.07.1999
Prospective
Prowess
criteria
33,543 All adult
(>15 yr)
ICU adm
23 ICUs
691
patients
752 septic
episodes
0.77/1,000
population
Mean 61
Male 57%
Brun-
Buisson et
al. 2004
France 19.11.2001-
02.12.2001
Prospective
Consensus
criteria
(1992)
3,738 206 546 0.95/1,000
population
Median 65
Male 67%
Van
Gestel et
al. 2004
The
Netherlands
11.12.2001-
12.12.2001
Prospective
Prowess
criteria
455 All adult
patients in
47 ICUs
134 0.54/1,000
population
Mean 64
Male 63%
Silva et al.
2004
Brazil 21.05.2001-
31.01.2002
Prospective
Consensus
criteria
(1992)
1,383 All adult
ICU adm in
5 ICUs
241 35.6/1,000
patient days
Median 66
Male 59%
Sundara-
rajan et al.
2005
Australia 01.07.1999-
30.06.2003
Retrospective
ICD-10 3,122,515 Hospital
discharge
data, all
ages
13,297 0.65/1,000
0.76/1,000
population
NA
Male 55%
(sepsis)
Vincent et
al. 2006
24
European
countries
01.05.2002-
15.05.2002
Prospective
Consensus
criteria
(1992)
3,147 All adult
(>15 yr)
ICU adm in
198 ICUs
Sepsis
1,177
Severe
sepsis
930
NA Median 65
Male 63%
(sepsis)
Harrison
et al. 2006
England,
Wales and
Northern
Ireland
01.12.1995-
31.01.2005
Retrospective
Prowess
criteria
343,860 All adult
(>16 yr)
adm in first
24h in 240
ICUs
92,672 0.46-
0.66/1,000
population
Mean 60-
62
Male 54%
(1995 and
2005)
Engel et
al. 2007
Germany One day
during 2003
Prospective
Consensus
criteria
(1992)
3,887 All adm in
454 ICUs
415 0.76-
1.1/1,000
population
NA
Cheng et
al. 2007
China 01.12.2004-
30.11.2005
Prospective
Consensus
criteria
(1992)
3,665 All adult
adm in 10
surgical
ICUs
318 NA Median 64
65%.
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Age has a strong influence on the incidence of severe sepsis. In the first large retrospective
epidemiology study concerning all ages, the incidence was lowest in children aged 5-14
years and in young adults (15-24 years), increasing slowly until the age of 59 years (Angus
et al. 2001 a). After 60 years, the incidence increased sharply and was 130 times higher in
the elderly over 85 years compared with children. The incidence of severe sepsis in infants
(<1 years) was as high as in adult patients aged 60-64 years. Eight percent of sepsis
patients were infants, 3.1% aged 1-19 years and 63% were over 60 years in another large
retrospective study (Sundarajan et al. 2005). Most incidence studies have included only
adult patients (Brun-Buisson et al. 1995; Alberti et al. 2002; Padkin et al. 2003; Vincent et
al. 2006; Harrison et al. 2006) but since the incidence in children is low, these studies can
be considered representative for the whole population.
The majority of patients in intensive care are male (Reinikainen et al. 2005) and the
proportion of men with sepsis or severe sepsis varies from 51.6% to 66.8% (Flaatten 2004;
Brun-Buisson et al. 2004). A female majority (51.9%) was found in one study, but in that
study, too, men were at increased relative risk (1.28, 95% CI 1.24-1.32) for sepsis (Martin
et al. 2003).
Race also influences the incidence of sepsis and severe sepsis. Black people have been
found to have higher incidence of sepsis than white people (Martin et al. 2003;
Dombrovskiy et al. 2007 a). The incidence is nearly double in black people compared to
white people (6.08 vs. 3.58/1,000 population respectively) (Barnato et al. 2008). This
difference in incidence remained after adjusting people for poverty or other social factors.
2.2.2 Incidence of organ dysfunction
Patients with severe sepsis often have more than one organ dysfunction or failure (Padkin
et al. 2003; Guidet et al. 2005; Vincent et al. 2006; Cheng et al. 2007). Organ dysfunction
has been defined as SOFA score < 2 and organ failure as SOFA score > 3 (Brun-Buisson et
al. 2004; Vincent et al. 2006). The most prevalent organ dysfunctions are acute respiratory
failure, septic shock and acute renal failure (Angus et al. 2001 a, van Gestel et al. 2004;
Vincent et al. 2006). Respiratory dysfunction is usually defined as acute lung injury (ALI)
with  PaO2/FiO2 relation  < 300 mmHg (< 40 kPa) or acute respiratory distress syndrome
(ARDS)  with  PaO2/FiO2 relation  < 200 mmHg (< 26.7 kPa). Respiratory dysfunction is
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found in 50%-96% of patients with severe sepsis (Guidet et al. 2005; Vincent et al. 2006).
Septic shock is present in 46%-72% (van Gestel et al. 2004; Engel et al. 2007). Up to 87%
of patients with more than one organ failure may have septic shock (Guidet et al. 2005).
Acute renal failure is present in 16%-51% depending on the definition of renal failure
(serum creatinine value or low urinary output) (Hoste et al. 2003; Vincent et al. 2006). The
lower occurrence was found in a retrospective study especially focusing on septic renal
failure. Another retrospective study using a new classification for renal failure named
RIFLE (Risk, Injury, Failure, Loss and End-Stage Kidney Disease) has found that sepsis is
the most frequent precipitating factor (47%) in patients with acute kidney injury (Bellomo
et al. 2004).
Haematological dysfunction is usually defined as low platelet count and is present between
12% and 22% of severe sepsis cases (Brun-Buisson et al. 2004; Engel et al. 2007). Sepsis
is the most common clinical condition associated with disseminated intravascular
coagulation (DIC), the most severe form of haematological dysfunction. In medical and
surgical ICU patients with clinical suspicion of DIC, 34% had confirmed diagnosis of DIC
according to the International Society for Thrombosis and Haemostasis (ISTH) criteria
(Taylor et al. 2001) and 77% of those patients had severe sepsis (Bakhtiari et al. 2004).
Hepatic failure is present as a new organ dysfunction only in 0.6%-1.3% of patients with
severe sepsis (Sundararajan et al. 2005; Angus et al. 2001 a). Central nervous system
dysfunction is most difficult to prove to be of septic origin and the occurrence varies
widely from 9% to 30% (Angus et al. 2001 a; Brun-Buisson et al. 2004). Severe sepsis
precipitated organ dysfunctions and failures in different studies are presented in Table 4.
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Table 4. Severe sepsis associated organ dysfunction.
Reference and
type of the
study
Definition
for organ
failure
Respiratory Cardio-
vascular
Renal Haematological Hepatic Central
nervous
system
Angus et al.
2001 a
Retrospective
ICD-9 46% 24% 22% 21% 1% 9%
Hoste et al.
2003
Retrospective
Study
specific
84% 56% 16% 67% 39%
Brun-Buisson et
al. 2004
Prospective
SOFA> 3 57% 56% 21% 12% 6% 30%
van Gestel et al.
2004
Prospective
Prowess
criteria
90% 72% 53% 23% 45% 23%
Guidet et al.
2005
Prospective
ICD-10
1 organ
failure or
> 2 organ
failures
74%
96%
15%
87%
7%
48%
0.3%
4%
4%
21%
Sundararajan et
al. 2005
Retrospective
ICD-10 23% 38% 35% 1% 17%
Vincent et al.
2006
Prospective
SOFA >3 50% 63% 51% 20% 12%
Engel et al.
2007
Prospective
Modified
Prowess
criteria
52% 46% 42% 22% 28%
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3.2 PATHOPHYSIOLOGY AND MEDIATORS IN SEVERE SEPSIS
"Severe sepsis and septic shock are clinical manifestations of a dysregulated immune
response to invasive pathogens" (Bochud and Calandra 2003).
Severe sepsis is a result of complex interactions between the infecting microorganism and
host's reaction to it. Briefly, the innate immunity must recognise invading microbes locally
in a specific tissue or in the systemic circulation. The stimulation of innate immunity will
activate intracellular signalling, which will result in the release of various cytokines like
tumour necrosis factor-? (TNF-?) and interleukin-1? (IL-1?). Cytokines have either
proinflammatory or anti-inflammatory properties. Host cells like monocytes, macrophages,
neutrophils, dendritic cells and natural killer (NK) cells are activated to eliminate invading
pathogens. The innate response also includes complement and coagulant system activation
and the production of acute phase proteins. The adaptive immunity consists of humoral and
cell-mediated responses to pathogens. Lymphocytes like B cells secrete immunoglobulins
to eliminate infecting microorganisms. Cell-mediated immunity includes different types of
T cells like T helper and natural killer cells. Some T cells like CD4+T cells can secrete
either proinflammatory or anti-inflammatory cytokines depending on the phase of the
immune response.
Anti-inflammatory immune suppression may follow the initial cytokine burst seen in
sepsis. The proinflammatory response may shift in excess to the anti-inflammatory state.
Apoptotic cell death seen in sepsis may cause anergy (loss of cell-mediated immune
response)  or  loss  of  CD4+T cells,  B  cells  or  dendritic  cells  (Hotchkiss  et  al.  1999).  The
central nervous system participates in the immune response by transmitting suppression of
proinflammatory cytokine production in macrophages by cholinergic anti-inflammatory
pathway mediated via the vagus nerve (Borovikova et al. 2000).
In addition, the polymorphism in TLRs or cytokine producing genes influences the balance
between proinflammatory and anti-inflammatory response and hence survival (Freeman
and Buchman 2000; Bochud et al. 2008; Wurfel et al. 2008.). Figure 2 presents simplified
pathogen–induced immune responses and their outcome.
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Figure 2. Pathogen–induced immune responses in host. Adopted from van der Poll and
Opal 2008 with permission.
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2.3.1 Innate immunity
Innate immunity detects invading pathogens with pattern-recognition receptors (PRRs),
such as Toll-like receptors (TLRs). PRRs recognise pathogen-associated molecular
patterns (PAMPs), which are molecules present in the cell-walls of bacteria, fungi, viruses
and parasites. PAMPs are pathogen-specific components like lipopolysaccharide (LPS) in
Gram-negative bacteria, lipoteichoic acid in Gram-positive bacteria, peptidoglycan in both
Gram-positive and negative bacteria, flagellin in flagellated bacteria, mannan in fungi like
Candida albicans and viral RNA. TLRs also recognise molecules able to stimulate the
innate immunity response in non-infectious conditions like tissue damage and hypoxia.
These molecules are called alarmins (Bianchi 2007) and together with PAMPs they are
included in damage-associated molecular patterns (DAMPs) (Bianchi 2007). PAMPs and
alarmins seem to have similar effects on PRRs during infectious and non-infectious
systemic inflammation. High mobility group box-1 protein (HMGB1) is one of the known
alarmins (Yang et al. 2007).
Toll-like receptors (TLRs) are transmembrane proteins present on the surface of immune
cells. Ten different TLRs have been found in humans. TLR-4 is specific for LPS and TLR-
2 for lipoteichoic acid and peptidoglycan. Intracellular signalling triggers transcription
factors like cytosolic nuclear factor ?B (NF-?B). Transcription of immune response genes
is increased and proinflammatory cytokines like TNF-? and IL-1? are released. NF-?B
also stimulates the release of anti-inflammatory cytokine IL-10. Monocytes and
macrophages are activated to secrete proinflammatory cytokines. Neutrophils and
endothelial cells are activated to produce adhesion molecules, which help in killing
pathogens, but may damage endothelium. Macrophages release mediators like vascular
endothelial growth factor (VEGF), which increases vascular permeability (Senger et al.
1983) and causes vasodilatation by induction of endothelial nitric oxide synthase (Kroll
and Waltenberger 1999).
2.3.2 Adaptive immunity
The adaptive immune response consists of humoral immunity like B cells secreting
immunoglobulins (antibodies) and cell-mediated immunity like different types of T cells.
CD4+T cells are helper cells, which secrete cytokines and CD8+T cells are cytotoxic killer
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cells (Delves and Roitt 2000 a). The CD4+helper cells are divided into Th1 and Th2 types
depending on the cytokines they produce (Mossman et al. 1986). Th1 type helper cells
secrete pro-inflammatory cytokines like TNF-?, IL-2 and interferon-? (IFN-?). Th2 type
helper cells secrete anti-inflammatory cytokines like IL-4, IL-6, IL-10 and IL-13 (Opal and
DePalo 2000). The balance between Th1 and Th2 response is influenced by the dose of the
pathogen (Abbas et al. 1996). Antibodies present pathogens to the components of the
innate immune system. Pathogens are destroyed by phagocytic cells with the help of the
complement system or antibodies binding on the receptors on phagocytic cells (Delves and
Roitt 2000 b).
2.3.3 Proinflammatory and anti-inflammatory cytokines
Cytokines are soluble protein mediators of the innate and adaptive immune response.
Cytokines are synthesized in response to stimulation of immune cells and they usually act
locally on adjacent cells, but high concentrations may enter the circulation and have
systemic effects. Many cytokines are pleiotrophic, which means that one cytokine can have
effects  on  different  cell  types.  In  addition,  similar  effects  can  be  caused  by  different
cytokines (Tayal and Kalra 2008). TNF-? and IL-1? are main proinflammatory cytokines,
which induce the activation of systemic inflammation. Cytokines like IL-4 and IL-10 are
solely anti-inflammatory and attenuate the proinflammatory response by decreasing the
secretion of certain cytokines or increasing the Th2 response. IL-6 is a pleiotrophic
cytokine, which has both proinflammatory and anti-inflammatory properties but the net
effect is considered to be anti-inflammatory (Opal and DePalo 2000). Common cytokines,
their cellular sources and main actions are listed in Table 5.
27
Table 5. Main proinflammatory and anti-inflammatory cytokines. Modified from
references Oberholzer et al. 2000, Delves and Roit 2000 b, Opal and DePalo 2000 and
Riedemann et al. 2003.
Cytokine Cellular sources Major activities
TNF-? Monocytes
Macrophages
Proinflammatory
-promotes inflammation
-activates macrophages and neutrophils
-induces the production of adhesion molecules in endothelial cells
-induces NO synthase in endothelial cells
-activates complement system
-activates coagulation
IL-1? Monocytes
Macrophages
Proinflammatory
-promotes inflammation
-activates macrophages and T cells
-potentiates the effects of TNF-?
IL-1ra Monocytes
Macrophages
Dendritic cells
Anti-inflammatory
-IL-1-receptor antagonist (ra)
-inhibits IL-1 –mediated cellular activation
IL-2 T helper cells (Th1) Proinflammatory
-activates lymphocytes, natural killer cells and macrophages
IL-4 T helper cells (Th2)
Mast cells
B cells
Stromal cells
Anti-inflammatory
-inhibits LPS-induced proinflammatory cytokine synthesis
-promotes Th2 lymphocyte development
IL-6 Monocytes
Macrophages
Endothelial cells
Polymorphonuclear
cells
Proinflammatory
-activates lymphocytes
-differentiation of B cells
-stimulates the production of acute phase proteins
Anti-inflammatory
-inhibits TNF and IL-1 production by macrophages
-stimulates adrenocorticotrophic hormone
IL-8 Monocytes
Macrophages
Endothelial cells
Proinflammatory
-chemotaxis of neutrophils, basophils and T-cells
IL-10 T cells (Th2)
B cells
Monocytes
Macrophages
Anti-inflammatory
-inhibits monocyte, macrophage and neutrophil cytokine production
-inhibits Th1 lymphocyte responses
-inhibits IL-2 and IFN-?
-inhibits NF-?B nuclear translocation
IL-11 Fibroblasts
Bone marrow
stromal cells
Anti-inflammatory
-inhibits monocyte/macrophage proinflammatory cytokine response
-promotes Th2 lymphocyte response
IL-13 T cells (Th2) Anti-inflammatory
-like IL-4
-attenuates monocyte and macrophage function
Interferon-?
(IFN-?)
T cells (Th1)
NK cells
Proinflammatory
-activates macrophages
inhibits Th2 lymphocyte responses
HMGB1 Macrophages
Dendritic cells
Natural killer cells
Necrotic cells
Proinflammatory
-stimulates monocytes to produce
TNF-?, IL-1?, IL-6
-regulates fibrinolysis by secreting PAI-1 and tPA
Macrophage
migration
inhibitory
factor (MIF)
Monocytes
Macrophages
T cells, B cells
Epithelial cells
Proinflammatory
-activates T cells
-stimulates macrophages
-modulates the expression of TLR4 on macrophages
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2.3.4 High mobility group box-1 protein
The data showing that high HMGB1 is associated with the severity of sepsis are mainly
from animal studies (Wang et al. 1999). Studies in humans have shown conflicting results.
HMGB1 has been associated with mortality in patients with severe sepsis (Wang et al.
1999) but in other patients with severe sepsis there was no correlation between HMGB1
and outcome (Sunden-Cullberg et al. 2005). Study results have not been reproduced even
in a specific group of patients such as patients with community-acquired pneumonia and
severe sepsis. A Danish study showed no associated mortality with HMGB1 concentrations
(Gaïni et al. 2007) while the other study in the United States showed a correlation (Angus
et al. 2007).
In experimental animal studies HMGB1 concentrations have been associated with organ
failures such as shock (Wang et al. 1999) and acute lung injury (Abraham et al. 2000).
HMGB1 concentrations have not been associated with organ dysfunctions in many other
studies, either (Sunden-Cullberg et al. 2005; Angus et al. 2007; van Zoelen et al. 2007).
HMGB1 concentrations were elevated in one study investigating patients with DIC and
high HMGB1 correlated with organ dysfunction and even with mortality (Hatada et al.
2005). However, only 20% of these patients had DIC associated with infection.
2.3.5 Vascular endothelial growth factor
VEGF has been studied extensively in various diseases like cardiovascular diseases,
malignancies, ocular neovascularisation, pre-eclampsia and inflammatory diseases such as
rheumatoid arthritis but there are only few human studies measuring VEGF in patients with
severe sepsis (Pickers et al. 2005; van der Flier et al. 2005). These studies have found that
high VEGF correlated with the severity of organ dysfunction and mortality. High plasma
VEGF has been correlated with ARDS (Thickett et al. 2001) while intrapulmonary VEGF
has been reduced in these patients (Thickett et al. 2002).
VEGF antagonist, a soluble VEGF receptor 1 (fms-like tyrosine kinase 1, sFLT) has been
found to inhibit the effects of VEGF (Maynard et al. 2003) and recent studies have
measured VEGF together with sFLT both in experimental (Tsao et al. 2007) and human
studies (Shapiro et al. 2008). In the latter study, patients with septic shock had increasing
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concentrations of VEGF and sFLT compared to the patients without shock and particularly
high sFLT correlated with APACHE II and SOFA scores. In the future, sFLT may have
diagnostic and even therapeutic applications (Shapiro et al. 2008).
2.3.6 Complement activation
The complement system is activated as a soluble part of innate immunity. The classic
pathway is precipitated by the component C1q, which is able to bind to immunoglobulins.
The alternative pathway is triggered after exposure to surface molecules containing
carbohydrates and lipids (i.e. LPS). The cleavage product of C3, the C3b, enhances
phagosytosis by binding to the pathogen (Delves and Roitt 2000 a). As a result of the
activation of any of these pathways, the concentrations of C3a, C4a and C5a are increased.
C5a is a strong chemoattractant and recruits inflammatory cells to produce cytokines and
activates phagocytic cells (Guo and Ward 2005). In addition, C5a may increase the
apoptosis of thymocytes and hence diminish the anti-inflammatory response (Guo et al.
2000).
2.3.7 Coagulation activation
The procoagulant system is activated by the innate immune response and as a consequence
the common procoagulant-anticoagulant balance is disturbed. Inflammation and
coagulation are linked with tissue factor (TF) pathway, thrombin, the protein C system and
the fibrinolytic system (Levi and van der Poll 2005). Proinflammatory cytokines,
particularly  IL-6,  provoke  endothelial  cells  to  expose  TF  and  activated  monocytes  to
secrete TF. Coagulant cascade in sepsis is activated by TF and results in the formation of
thrombin and fibrin clots in microvasculature (Thijs et al. 1993).
2.3.8 Immune suppression and apoptosis
Immune response in sepsis may be impaired by excess immunosuppression caused by
anergy (unresponsiveness to antigen stimulation) of the immune cells or apoptosis
(programmed  cell  death)  of  immune  cells  (Hotchkiss  et  al.  1999).  Anergy  of  T  cell
proliferation and depressed production of IL-2 and TNF-? have been found in patients with
lethal intra-abdominal sepsis (Heidecke et al. 1999).
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Extensive lymphocyte apoptosis have been shown to occur in both animal (Hiramatsu et al.
1997) and human sepsis studies (Hotchkiss et al. 1999). Apoptosis is initiated by caspases
(Budihardjo et al. 1999) and glucocorticoids are able to induce it (Fukuzuka et al. 2000).
CD4+T cells, B cells and also follicular dendritic cells are the most abundant cells to die
(Hotchkiss et al. 2001; Tinsley et al. 2003), but macrophages do not suffer from apoptosis
(Hotchkiss et al. 2002). In addition, apoptotic cells induce monocytes to secrete anti-
inflammatory cytokines like IL-10 and decrease the secretion of proinflammatory
cytokines like TNF-? and IL-1 (Voll et al. 1997). Unlike apoptotic cells, necrotic cells
induce inflammatory response (Green and Beere 2000).
2.3.9 Cholinergic anti-inflammatory pathway
The central nervous system may influence the innate immune response via the efferent
parasympathetic anti-inflammatory pathway (Borovikova et al. 2000). A nicotinic
acetylcholine receptor alpha7 (?7) subunit transmits the acetylcholine effect on
macrophages and its stimulation inhibits the TNF release (Wang et al. 2003). Treatment
with nicotine, an ?7 agonist, has also been reported to reduce HMGB1 release on
macrophages in experimental models of sepsis (Wang et al. 2004). Oxytocin, a hormone
with neurotransmitter properties, has excitatory effects on vagal neurons and was recently
shown to decrease cytokine response to bacterial endotoxin in healthy men (Clodi et al.
2008).
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2.4 TREATMENT OF SEVERE SEPSIS
2.4.1 Fluid therapy
Fluid resuscitation is essential in treating sepsis-induced cardiovascular failure and septic
shock. Absolute and relative hypovolaemia are caused by external and internal fluid losses
(sweating, diarrhoea, fluid shifts to the peritoneal cavity) and the maldistribution of
circulation due to vasodilatation. Hypovolaemia may lead to reduced cardiac output, low
blood pressure and disturbances in microcirculation. The time for fluid resuscitation, the
adequate amount of fluids and fluid treatment protocols with defined endpoints seem to be
more important for good outcome than the type of fluids (Rivers et al. 2001).
The type of fluids
Meta-analyses concerning fluid resuscitation in general ICU population show no
differences in outcome between crystalloids and colloids (Choi et al. 1999; Perel et al.
2007). However, although there are no safety or efficacy differences in fluid resuscitation
between colloids (albumin, gelatins and hydroxyethyl starches) in general (Bunn et al.
2008), there are safety concerns regarding in patients with severe sepsis. The risk for acute
kidney injury (AKI) with hydroxyethyl starches (HES) but not gelatines has been found to
increase (Schortgen et al. 2001). The acute renal failure and need for continuous renal
replacement therapy with 10% high molecular weight HES solutions (200/0.5) increased in
patients with severe sepsis (Brunkhorst et al. 2008) and hyperoncotic colloids are not
recommended because of possible risk of renal injury in patients with shock for any cause
(Schortgen et al. 2008). Albumin has been suspected to increase mortality in critically ill
patients (Cochrane Injuries Group Albumin Reviewers 1998) but was found to be safe
compared with saline in the SAFE Study (Finfer et al. 2004 b). The mortality rates did not
differ in a subgroup of patients with severe sepsis, either. In Finland, albumin is not
recommended instead of crystalloids or other colloids (Pettilä and Ruokonen 2005).
The fluid challenge
The concept of fluid challenge is based on the patient's response to fluids administered
(Weil et al. 1979). The use of fluid challenge is not limited to haemodynamically unstable
septic patients but can be used in any patient group with hypovolaemia. The fluid
challenge protocol should include the type of fluid, the rate of fluid administration, the
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endpoints and safety limits (Vincent and Weil 2006). As discussed earlier, the type of fluid
can be chosen quite freely. The proposed rate of fluid administration has varied from 50-
200 ml in 10 minutes to 500-1000 ml of crystalloids or 300-500 ml of colloids in 30
minutes (Weil et al. 1979; Dellinger et al. 2008). The main target in fluid challenge should
be haemodynamic improvement. However, the precise end points for fluid challenge or
resuscitation are not self-evident or universally accepted. Mean arterial pressure (MAP),
cardiac index (CI), cardiac filling pressures such as central venous (CVP) and pulmonary
artery wedge (pcwp) pressures, mixed venous saturation (SvO2) or central venous
saturation (ScvO2) and stroke volume variation (SVV) (Marx et al. 2004) have been used
as end points.
The CVP has been chosen for one of the fluid resuscitation goals in severe sepsis treatment
guidelines (Dellinger et al. 2008), but cardiac filling pressures have been shown not to
predict hemodynamic response to fluid challenge (Osman et al. 2007). SVV does not work
at least on pressure support ventilation in patients with septic shock (Perner et al. 2006).
The individual safety limits for fluid challenge technique are needed to avoid congestive
heart failure and pulmonary oedema (Vincent and Weil 2006). The fluid challenge
technique should be used especially in early treatment of haemodynamically unstable
patients and once the need for additional fluids has passed, the fluid administration should
be decreased. Excessive fluids can be harmful in patients with acute lung injury. Patients
with restricted fluids are weaned earlier from the ventilator and have shorter length of stay
in the ICU than patients with liberal fluid management (Sakr et al. 2006).
2.4.2. Vasoactive treatment
The target for vasoactive treatment
Severe sepsis and septic shock as the most severe form of cardiovascular dysfunction cause
absolute or relative hypovolaemia, vasodilatation, direct myocardial depression and
consequently hypotension, changes in blood flow distribution and perfusion abnormalities.
Fluid resuscitation alone can alleviate haemodynamic disturbances only in a mild
cardiovascular dysfunction and patients with septic shock need vasoactive support in 85%
of cases (Annane et al. 2003). Mean arterial pressure (MAP) over 65 mmHg has been
recommended by the Surviving Sepsis Campaign guidelines (Dellinger et al. 2008). The
optimal target level for MAP is not known and it may vary between individual patients
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with different pre-existing comorbidities. MAP under 65 mmHg may impair outcome
(Varpula et al. 2005), but high MAP up to 90 mm Hg with rapidly increasing systemic
vascular resistance increases mortality as well (Lopez et al. 2004). However, increasing
MAP from 65 mm Hg to 85 mm Hg with NE in a small group of patients with septic shock
did not increase or decrease the systemic oxygen metabolism, diuresis or splanchnic
perfusion (LeDoux et al. 2000).
Myocardial depression has been found in 44-50% in patients with septic shock (Parker et
al. 1984; Charpentier et al. 2004). Survivors usually recover completely, but myocardial
adrenergic hyporesponsiveness found in septic shock can persist for several days, resolving
in 8-10 days (Parker et al. 1984; Cariou et al. 2008). The target for inotropic treatment is to
increase the cardiac output (CO) and oxygen delivery (DO2). Low SvO2 or ScvO2 can be
used as markers of inadequate oxygen delivery, but the latter corresponds poorly in
patients with severe sepsis (Varpula et al. 2006). Increasing oxygen delivery to
supranormal values does not decrease mortality in patients with critical illness (Hayes et al.
1993; Gattinoni et al. 1995). In the former study 40% of the patients included had severe
sepsis  or  septic  shock,  in  the  latter  study  the  proportion  of  septic  patients  cannot  be
identified. The SSC guidelines do not recommend increasing the CI to supranormal levels
in patients with severe sepsis, either (Dellinger et al. 2008).
Vasopressor drugs
Dopamine is a precursor of norepinephrine and epinephrine. Its effects are dose-dependent:
stimulation of vasodilatory dopaminergic DA1 receptors in renal and mesenteric vessels at
low doses (<5 ?g/kg/min), ?-adrenergic stimulation with increasing contractility and heart
rate at 5-10 ?g/kg/min and ?-adrenergic stimulation with vasoconstriction at high doses
>10 ?g/kg/min. However, dopamine does not prevent acute renal failure (Bellomo et al.
2000). Dopamine can increase splanchnic blood flow, but decreases the mucosal flow and
hence oxygen delivery (Giraud et al. 1984). Dopamine can have different unwanted
endocrinological effects such as suppressing prolactin release (Bailey et al. 1997) and
impairing growth hormone release (van den Berghe et al. 1994). Dopamine administration
may increase mortality compared with patients not treated with dopamine for septic shock
treatment (Sakr et al. 2006).
Norepinephrine (NE) is an ?-adrenergic agonist with weak ?-adrenergic agonist effects. It
is a potent vasopressor which can be effective in dopamine-resistant septic shock (Martin
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et al. 1994; de Backer et al. 2003). The effect of NE on splanchnic blood flow and oxygen
delivery has been found to be similar to that of dopamine in moderate septic shock but
more advantageous than epinephrine in severe septic shock (de Backer et al. 2003). While
increasing systemic oxygen delivery, NE also increases mucosal pH, a surrogate marker of
tissue oxygenation. NE appears to have a favourable effect on the balance between
splanchnic oxygen delivery and oxygen utilization (Marik et al. 1994). In all, the influence
of dopamine or NE on regional blood flow cannot be predicted from changes in systemic
blood flow and the increased oxygen demand may lead to increased risk for tissue hypoxia
in the splanchnic region (Ruokonen et al. 1993). NE and dopamine are the first line
vasopressors recommended by the SSC guidelines.
Epinephrine is a strong ?-adrenergic and ?-adrenergic agonist. Epinephrine increases blood
pressure and cardiac index in patients with septic shock in a highly dose dependent manner
(Moran et al. 1993) but it impairs the splanchnic blood flow compared with the
combination of NE and dobutamine (Levy et al. 1997) or NE alone (de Backer et al. 2003).
Epinephrine is not recommended as a first line vasopressor agent in septic shock (Dellinger
et al. 2008). However, one recent study found no difference in mortality in patients with
septic shock treated with epinephrine alone or with NE combined with dobutamine
(Annane et al. 2007).
Arginine vasopressin (AVP) is an endogenous peptide hormone synthesized in the
hypothalamus and secreted by the pituitary gland. It directly activates V1 receptors in
vascular smooth muscle cells leading to vasoconstriction and increases the vascular
responsiveness to catecholamines (Medina et al. 1997). AVP may also inhibit the smooth
muscle nitric oxide production in inflammatory states (Kusano et al. 1997). The activation
of V2 receptors on renal tubules and water resorption causes the antidiuretic effect of the
hormone. V3 receptors are situated in the pituitary gland and have central effects, such as
ACTH release. In hypotensive states, AVP should be maintaining the blood pressure, but
AVP plasma levels have been found to be inadequately low in septic shock (Landry et al.
1997). Low doses of AVP infusion increases arterial blood pressure alone or in
combination with NE even in catecholamine–resistant vasodilatory shock (Landry et al.
1997; Dünser et al. 2003 a). Vasopressin should be used as a low-dose infusion (between
0.01 and 0.04 U/min) to prevent harmful side effects (Beale et al. 2004). As a potent
vasoconstrictor, AVP may be harmful and may cause a decrease in CO and even cardiac
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arrest (Holmes et al. 2001), mesenterial ischaemia (van Haren et al. 2003. Klinzing et al.
2003) and ischaemic skin lesions (Dünser et al. 2003 b). AVP may also induce
thrombocytopenia by platelet aggregation (Dünser et al. 2004). A recent multicentre,
randomized, double-blind trial found no difference in mortality or side effects in patients
with moderate or severe septic shock treated with NE or low-dose AVP (max 0.03 U/min)
(Russell et al. 2008). Patients with severe ischaemic heart disease or mesenteric ischaemia
were excluded from the study and this may have influenced the safety profile of AVP.
Surprisingly, there was a trend for a lower mortality in patients with less severe septic
shock treated with AVP. Low dose AVP may be more advantageous in replenishing AVP
reserves than in just using it as a high-dose vasoconstrictor alone.
Terlipressin is a long-acting synthetic vasopressin analogue, which has higher V1 receptor
activity than AVP. Terlipressin been used as a bolus injection to stabilize haemodynamics
in septic shock (Leone et al. 2004; Morelli et al. 2004). Terlipressin reduces CI, DO and
oxygen consumption and may carry a risk for sustained global and regional
vasoconstriction (Albanese et al. 2005). It should possibly be given together with an
inotrope like dobutamine to maintain CI (Morelli et al. 2008). Neither AVP nor terlipressin
are recommended by the SSC guidelines as first line agents in adult septic shock (Dellinger
et al. 2008).
Inotropic drugs
Dobutamine, a synthetic inotrope has a direct effect on ?1 cardiac receptors and only a
slight effect on ? and ?2 vascular receptors (Tuttle et al. 1975). Dobutamine was first
compared with dopamine in patients with septic shock and was recommended in cases with
high filling pressures and cardiac failure (Regnier et al. 1979; Jardin et al. 1981). Since
then  it  has  been  widely  used  to  increase  CO  and  DO  in  patients  with  severe  sepsis  and
septic shock (Shoemaker et al. 1986; Vincent et al. 1990). Dobutamine was even able to
increase DO to supranormal levels (Shoemaker et al. 1988; Tuchschmidt et al. 1992), but
as pointed out earlier, this was not found to be advantageous (Hayes et al. 1993; Gattinoni
1995). Dobutamine is the first line inotrope to be used in septic shock (Dellinger et al.
2008).
Levosimendan, a calcium-sensitizer with inotropic and vasodilative properties has been
shown to be effective in acute and chronic heart failure (Slawsky et al. 2000; Follath et al.
2002) even if it has not affected mortality compared with dobutamine (Mebazaa et al.
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2007). Levosimendan increases CI in sepsis-induced myocardial depression both in
experimental sepsis (Oldner et al. 2001) and in patients with septic shock (Morelli et al.
2005). Levosimendan alleviates right ventricular dysfunction in patients with septic shock-
associated acute respiratory distress syndrome (ARDS) (Morelli et al. 2006).
Levosimendan increases intestinal blood flow and gut oxygen delivery in experimental
endotoxemia (Oldner et al. 2001; Schwarte et al. 2005; Dubin et al. 2007) and increased
gastric mucosal blood flow has been shown in patients with septic shock (Morelli et al.
2005). Even though levosimendan has many advantageous effects in sepsis-induced
myocardial depression, there are as yet no studies to show the reduction in mortality
compared with dobutamine.
2.4.3 Early goal-directed therapy
Fluid resuscitation and vasoactive therapy have been the cornerstones of haemodynamic
treatment in severe sepsis for nearly two decades (Shoemaker et al. 1991) but the concept
of early treatment with several strict predefined goals was introduced by Rivers et al. 2001.
This early goal-directed therapy (EGDT), which was conducted mainly in the emergency
department in the first six hours, had targets for MAP, CVP, urine output and ScvO2. Fluid
resuscitation, vasopressor therapy, dobutamine and packed red blood cells were the
treatments of choice to achieve predefined targets. The reduction in mortality was 16% in
the goal-directed group compared with the control group. This study has been criticized for
its patient selection and for being only a single-centre study (Ho et al. 2006), but it was the
first study to show a mortality reduction using a protocol with goals for basic
haemodynamic variables. The EGDT concept has been widely used after publication and
decreased mortality after implementation of EGDT protocol has been documented in
various hospitals (Gao et al. 2005; Micek et al. 2006; Jones et al. 2007).
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2.4.4 Antimicrobial treatment
As a disease of infectious origin, severe sepsis needs to be treated with antimicrobial
agents as well as adequate source control whenever possible. Experimental studies in
septic shock have shown that haemodynamic treatments need to be combined with
antimicrobial agents and vice versa for better survival (Natanson et al. 1990). Appropriate
empirical antimicrobial treatment has been shown to decrease mortality in blood-born
infections  (Leibovici  et  al.  1998;  Ibrahim  et  al.  2000).  Treatment  should  be  started  with
broad-spectrum antibiotics, which can later be matched up with the causative agent. The
timing of antimicrobial treatment is as important as effectiveness and should be initiated as
soon as possible. Early antimicrobial treatment administered within on hour after
documented hypotension in patients with septic shock has been shown to increase survival
compared with later administration. One-hour's delay in antibiotic administration decreases
the probability of survival by 12% in septic shock (Kumar et al. 2006).
2.4.5 Mechanical ventilation
Respiratory failure is the most common organ dysfunction in severe sepsis affecting as
many as 74%-96% of patients (Guidet et al. 2005). In studies on ALI or ARDS 32%-83%
of  patients  were  septic  (Amato  et  al.  1998;  Bersten  et  al.  2002).  The  first  study  ever  to
show decreased mortality with a special method of mechanical ventilation was the
ARDSnet Study, and in that study nearly a third of patients had sepsis-related respiratory
failure. The six months mortality decreased from 39.8% to 31% in patients ventilated with
low tidal volumes (< 6 ml/kg predicted body weight) compared with traditional ventilation
(The  Acute  Respiratory  Distress  Syndrome  Network  2000).  These  patients  were  also
treated with plateau pressures under 30 cm of water. However, higher plateau pressures (up
to  40  cm  of  water)  were  not  associated  with  increased  mortality  or  complications  when
used with low tidal volume ventilation (Meade et al. 2008). Nearly half of these patients
had sepsis-originated ALI or ARDS. Patients with severe sepsis are treated with a low tidal
volume protocol, because at the moment there is no evidence that septic lung injury should
be treated differently from other lung injuries.
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2.4.6 Renal replacement therapy
Severe sepsis is complicated up to 42%-53% by acute kidney injury (AKI) (van Gestel et
al. 2004; Bagshaw et al. 2008) and as many as 70% of those patients may need renal
replacement therapies (Hoste et al. 2003). In studies on AKI incidence or different
treatment modalities 35%-63% of patients were septic (Brivet et al. 1996; Vinsonneau et
al. 2006; Prescott et al. 2007). Even though two meta-analyses and one controlled study
found no differences in mortality with continuous renal replacement therapies or
intermittent haemodialysis in acute renal failure (Kellum et al. 2002; Tonelli et al. 2002;
Vinsonneau et al. 2006), continuous treatments are better tolerated and facilitate better
fluid balance control in patients with unstable haemodynamics and septic shock. The
higher dosage of renal replacement therapy decreased mortality in studies using
intermittent haemodialysis (Schiffl et al. 2002) or continuous veno-venous haemofiltration
(Ronco et al. 2000). In the former study 36% and in the latter study 13% of the study
patients were septic. However, a recent prospective study could not confirm this positive
dosage effect on mortality or recovery of kidney function. In this large study, over 50% of
study patients had severe sepsis-related acute kidney injury (VA/NIH Acute Renal Failure
Trial network 2008). High volume haemofiltration has been shown to remove cytokines
(Bellomo et al. 1993), attenuate vasopressor requirements and even have a trend towards
decreased mortality in septic shock (Oudemans-van Straaten 1999; Cole et al. 2001;
Ratanarat et al. 2005), but prospective, randomized, controlled trials are lacking.
2.4.7 Adjuvant treatments
Glucose control
Intensive insulin treatment with strict glycaemic control was introduced and widely
accepted after a study showing a morbidity and mortality reduction in critically ill surgical
patients  (van  den  Berghe  et  al.  2001).  Patients  were  mostly  (63%)  postoperative  cardiac
patients. Mortality was decreased from 8% in patients with blood glucose levels between
10.0-11.1 mmol/l to 4.6% in patients with strict blood glucose levels between 4.4-6.1
mmol/l. The reduction in morbidity was most obvious in bloodstream infections and acute
renal failure and the reduction in mortality due to severe sepsis and multiple organ failure
was most prominent. This study has been criticized for patient selection, for high mortality
in the control group and high glucose administration (Brunkhorst et al. 2008). A second
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study in medical critically ill patients failed to show any mortality reduction (van den
Berghe et al. 2006). In that study it was impossible to identify the proportion of patients
with severe sepsis. A recent large multicentre study on patients with severe sepsis found no
benefit from strict glucose control (Brunkhorst et al. 2008). The study was preterminated
because of risk of potentially harmful hypoglycaemia (<2.2 mmol/l) in the strict protocol
group (17% vs. 4.1% in the control group). The control of the blood glucose level seems to
be more important than the absolute levels of exogenous insulin infused and the possible
mortality benefit may be greatest below a predicted glucose level of 8.0-11.1 mmol/l
(Finney et al. 2003). Target glucose level under 8.3 mmol/l may have the best risk-benefit
ratio, probably also in patients with severe sepsis. A large multi-centre, randomised open
label glucose control study with targeted 6,000 patients is ongoing and will hopefully
demonstrate the appropriate glucose level with maximal advantages and minimal risks
(http://www.controlled-trials.com/ISRCTN049682759. NICE-SUGAR study). In addition,
it is clinically important to pay attention to bedside glucose measurement, as point-of-care
glucometers may measure incorrectly high glucose values in the presence of low
hematocrit (Mann et al. 2008).
Corticosteroids
High dose corticosteroids (e.g. methylprednisolone 30 mg/kg intravenously) were studied
in treating severe sepsis or septic shock in the 1980´s after positive findings in
experimental animal studies and one small human study (Schumer 1976). Large,
randomised studies could not show any reduction in mortality and in fact high dose
corticosteroids were found to be harmful (Sprung et al. 1984; Bone et al. 1987; The
Veterans Administration Systemic Sepsis Cooperative Study Group 1987; Luce et al.
1988). Meta-analyses later confirmed these findings and concluded that high dose
corticosteroids should not be used in severe sepsis and septic shock (Cronin et al. 1995;
Minneci et al. 2004).
Low dose corticosteroid therapy was introduced after it was found that relative adrenal
insufficiency in patients with septic shock could lead to vasopressor-resistant hypotension
and increased mortality (Rothwell et al. 1991; Soni et al. 1995). Increased survival and
better shock reversal were achieved by low dose corticosteroids in prospective, single-
centre studies (Bollaert et al. 1998; Briegel et al. 1999; Keh et al. 2003). As high dose
corticosteroids were usually administered in the first 24 hours in older studies, low dose
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corticosteroid treatment (e.g. hydrocortisone 200-300 mg per day intravenously) was
administered over 5 days.
The first prospective, multicentre study was published 2002. In that study by Annane, 77%
of patients with septic shock were non-responders to adrenocorticotropic hormone (ACTH)
stimulation test and suffered from relative adrenal insufficiency. Low dose corticosteroid
treatment with hydrocortisone 50 mg every 6 hours and fludrocortisone 50 ?g every 24
hours for 7 days decreased mortality in patients with adrenal insufficiency and shortened
the time for shock reversal (Annane et al. 2002). The result of this study was quickly and
widely accepted. However, an adequate diagnosis of relative adrenal insufficiency in
critically ill patients has been difficult to obtain (Loisa et al. 2005; Lipiner-Friedman et al.
2007; Sprung et al. 2008). Free cortisol levels have been measured instead of total cortisol
concentrations, but these have not been helpful in diagnosing relative adrenal insufficiency
(Hamrahian et al. 2004; Bendel et al. 2008).
The study by Annane was criticized for the statistical significance of 28-day mortality
reduction in non-respondent group and high proportion of patients with earlier exposure to
etomidate,  a  known  suppressor  of  adrenal  function  (Wagner  et  al.  1984).  A  recent  large
multicentre  trial  (CORTICUS)  failed  to  show any  reduction  in  mortality  in  patients  with
septic shock, whether they were non-responders to the ACTH test or not, and whether they
received hydrocortisone or not. Hydrocortisone treatment hastened shock reversal, but was
associated with more episodes of superinfection (Sprung et al. 2008). However, as the
patients in Annane's study were sicker than the patients in the Corticus Study at
randomisation, those patients with vasopressor-unresponsive shock may have benefited
from early low dose corticosteroid treatment (Sprung et al. 2008). A new term "critical
illness–related corticosteroid insufficiency" (CIRCI) is now introduced. CIRCI is based on
more clinical suspicion and judgement than laboratory values in patients with vasopressor-
dependent septic shock (Marik et al. 2008).
Activated protein C
Inflammation and sepsis can downregulate fibrinolytic and protein C anticoagulant
pathways, (Esmon et al. 1999) and recombinant human activated protein C (rhAPC) has
been shown to reduce mortality in patients with severe sepsis in the large, randomised,
multicentre Prowess Study (Bernard et al. 2001). The majority of patients (76%) in the
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Prowess trial had two or more organ dysfunctions and the mean APACHE II score was 25
(SD 7.8). The absolute mortality reduction was 6.1% and relative mortality reduction
19.4% in rhAPC-treated patients. The anti-inflammatory and fibrinolytic effects were
demonstrated by decreased IL-6 and fibrin degradation products (D-dimer) levels in
patients treated with rhAPC. As a physiological anticoagulant, rhAPC was associated with
serious bleeding complications in 3.2% vs. 2% in the control group. Other studies with
rhAPC  in  adult  patients  with  lower  risk  of  death  or  in  children  have  failed  to  show  any
mortality reduction (Abraham et al. 2005; Nadel et al. 2007) and instead have been
associated with increased risk of serious bleeding complications (Abraham et al. 2005;
Goldstein et al. 2006). A recent Cochrane Database review found "no evidence suggesting
that  APC  should  be  used  for  treating  patients  with  severe  sepsis  or  septic  shock,  unless
additional randomised controlled trials provide evidence of a treatment effect" (Martí-
Carvajal et al. 2008).
2.4.8 Protocols and guidelines
The Surviving Sepsis Campaign has published the Resuscitation Bundle for the first 6
hours and the Management Bundle for the first 24 hours after hospital admission and the
diagnosis of severe sepsis (http://www.survivingsepsis.org/implement/bundles). These
bundles are presented in Table 6. Mortality in severe sepsis has decreased when these SSC
guidelines or modified protocols have been implemented in a few units (Gao et al. 2005;
Kortgen et al. 2006) or nationwide (Ferrer et al. 2008). The Spanish study was able to
show prospectively how better compliance with the bundles decreased mortality (Ferrer et
al. 2008). One year after the study, the compliance with the resuscitation bundle had
declined, but compliance with the management bundle and the effect on mortality
remained unchanged.
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Table 6. Resuscitation Bundle for the first 6 hours and the Management Bundle for the
first 24 hours. Adopted from the Severe Sepsis Campaign with permission.
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2.5 OUTCOME OF SEVERE SEPSIS
2.5.1 Short-term mortality
Severe sepsis is associated with high short-term mortality, ranging from 27% to 59%
(Brun-Buisson  et  al.  1995;  Flaatten  et  al.  2004).  ICU  and  hospital  mortalities  are
representative of the short term outcome and ICU and hospital mortalities for severe sepsis
are presented in Table 7.
Table 7. Short-term mortality in severe sepsis. NA=not applicable.
Reference Country ICU mortality Hospital mortality
Salvo et al.
1995
Italy NA 52%
Rangel-Frausto et al.
1995
USA NA 20%
Brun-Buisson et al.
1995
France 56% 59%
Sands et al.
1997
USA NA 34% (28 days)
Angus et al.
2001 a
USA NA 28.6%
Martin et al.
2003
USA NA 27.8%-
17.9% in sepsis
Padkin et al.
2003
England, Wales and
Northern Ireland
35% 47%
Flaatten 2004 Norway NA 27%
Finfer et al.
2006
Australia 26.5% 37.5%
Brun-Buisson et al.
2004
France NA 35% (30 days)
41.9% (2 months)
Silva et al.
2004
Brazil 21.8% 46.9%
Sundarajan et al.
2005
Australia NA 31.1%
Vincent et al.
2006
24 European countries 32.2% NA
Engel et al.
2007
Germany 48.4% 55.2%
Cheng et al.
2007
China NA 48.7%
Dombrovskiy et al.
2007 b
USA NA 45.8% (1993)
37.8% (2003)
Case fatality has decreased over time, even though overall severe sepsis mortality
accumulates due to the annual incidence increase as shown in Figure 3 (Martin et al. 2003;
44
Dombrovskiy et al. 2007 b). Mortality is affected by age, gender, race, co-morbidities, the
number  of  organ  dysfunctions  and  underlying  genetic  factors,  as  well  as  the  ICU
performance in treating patients with severe sepsis.
Figure 3. Age-adjusted hospitalization (A), mortality (B) and case fatality (C) rates for
severe sepsis in the United States in 1993–2003. Adopted from Dombrovskiy et al. 2007 b
with permission.
Age is also an independent predictor of outcome in severe sepsis and mortality increases
linearly by age (Angus et al. 2001 a; Martin et al. 2006). Mortality in male gender may be
lower (Alberti et al. 2003; Dombrovskiy et al. 2007 b) or higher compared to females
(29.3% vs. 27.9%), but differences in underlying disease and site of infection may explain
this finding (Angus et al. 2001 a). However, gender has had no influence on mortality in
some studies (Wichmann et al. 2000; Engel et al. 2007).
The effect of race on mortality in severe sepsis has been investigated in large retrospective
studies in USA. The study by Martin found the highest sepsis mortality in black men
(Martin et al. 2003). A recent large study on racial variation between white, black and
Hispanic patients found that the highest overall mortality and case fatality was among
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black patients and the difference was obvious already among young adults. The mortality
in  Hispanic  patients  did  not  differ  from  the  mortality  in  white  patients  in  spite  of  lower
incidence (Barnato et al. 2008). Black patients had the highest age-and gender-adjusted
hospital case fatality compared with Hispanics or whites (26.1%, 24.6% and 24.2%
respectively). Black patients were less likely to receive intensive care, but also had the
highest mortality when treated in intensive care (32.1% for blacks, 29.3% for whites,
p<0001). Black patients were treated in hospitals with lower hospital performance in
severe sepsis compared to white patients and this might explain the higher case fatality
according to the investigators. However, one earlier study reported similar case fatality
between black patients and white patients and no disparities in the quality of treatment, but
population-based mortality was higher in blacks in this study, too (Dombrovskiy et al.
2007 a).
Figure 4. Age-specific mortality rates for all cases of severe sepsis and for those with and
without underlying comorbidity in the United States. Adopted from Angus et al. 2001 a
with permission.
Not surprisingly, co-morbidities such as chronic liver failure, chronic heart failure and
immunosuppression in patients with severe sepsis have an exacerbating effect on mortality
(Angus et al. 2001 a; Alberti et al. 2003; Esper et al. 2006). The influence of age and co-
morbidities on mortality is shown in Figure 4.
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The number of dysfunctioning or failing organs has a strong influence on mortality. The
ICU mortality with four organ failures was ten-fold compared to patients with one organ
failure in the European Sepsis Study (Vincent et al. 2006). The hospital mortality in
patients with at least two organ failures is four-hold compared to patients with only one
organ failure (49% vs. 11% respectively) (Guidet et al. 2005). Especially hepatic, renal and
respiratory failures are associated with poor outcome (Angus et al. 2001 a).
Except gender and race, other genetic factors such as gene polymorphism have also been
shown to have influence on mortality in severe sepsis. Different genotypes such as IL-1?
and IL-1? genes (Ma et al. 2002), IL-1 receptor antagonist gene (Arnalich et al. 2002; Ma
et al. 2002), CD14 promoter gene (Gibot et al. 2002), mannose-binding lectin (Gordon et
al. 2006) and protein C-1641 (Walley et al. 2007) have been found to affect mortality in
human studies.
The performance of individual intensive care departments on treating patients with severe
sepsis has an impact on mortality. This variation in outcome has been found between
countries (Vincent et al. 2006), private and community hospitals (Silva et al. 2004) or
analogous hospitals within the same country (Yu et al. 2003). The differences in outcome
can be accounted for by the disparities between patients and severity of illness, but also by
different treatment modalities (Yu et al. 2003). Finally, decisions to withhold or withdraw
intensive care and life-sustaining treatments are most often taken on patients with severe
co-morbidities or incurable acute illness. These decisions have significant influence on
short-term outcome in patients with critical illness (Azoulay et al. 2003).
2.5.2 Long-term mortality
"The most important endpoint by which to evaluate the outcome of critically ill patients is
long term survival" (Williams et al. 2008)
Patients surviving critical care are involved with increased risk of death for the next 15
years compared with the general population (Williams et al. 2008). Age, co-morbidities
and primary diagnosis have the greatest effect on the long-term outcome in patients with
critical illness in general (Niskanen et al. 1996; Williams et al. 2008) and have been shown
to have influence on patients with severe sepsis as well (Weycker et al. 2003).
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Until now most studies on severe sepsis have been restricted to short-term outcome such as
ICU and hospital mortality. However, long-term outcome evaluation should be included in
clinical trials in addition to short-term follow-up (Angus et al. 2003 a). One-year mortality
has been as high as 51.4% and five-year mortality 74.2% among patients with severe sepsis
when  the  majority  of  patients  have  been  over  65  years  old  (Weycker  et  al.  2003).  Even
with younger patients, two-year mortality is up to 57% in patients with severe sepsis
(Korošec Jagodi? et al. 2006). Patients with severe sepsis have decreased long-term
survival compared to patients with other critical illness (Granja et al. 2004) or with trauma
(Korošec Jagodi? et al. 2006).
2.5.3 Quality of life, quality-adjusted life years and cost of treatment
Quality of life
The outcome after critical illness comprises not only survival but also quality of life. It is
important to evaluate quality of life (QOL) when assessing long-term outcome in patients
with severe sepsis (Marshall et al. 2005). Critical illness and its sequelae have an influence
on QOL. Prolonged neuropsychological impairment has been found in survivors of
intensive care (Jackson et al. 2003; Jones et al. 2006) and experimental animal studies have
shown learning and memory impairment after sepsis (Barichello et al. 2008; Tuon et al.
2008).
There is no consensus on the time most suitable for QOL assessment (Black et al. 2001),
but a minimum of 6 months after critical illness has been recommended (Angus et al. 2003
a). QOL has been evaluated within 6-12 months after hospital discharge (Niskanen et al.
1999; Eddleston et al. 2000; Graf et al. 2005) and even in 5-12 years after treatment in
intensive care (Flaatten et al. 2001; Graf et al. 2005; Kaarlola et al. 2006). These studies
with general ICU patients have also included patients with severe sepsis. Studies limited to
patients with severe sepsis have assessed QOL at 6 months (Granja et al. 2004), 16 months
(Heyland et al. 2000) or 2 years (Korošec Jagodi? et al. 2006).
Various instruments have been used to measure QOL in patients with critical illness. The
Nottingham Health Profile (NHP) (Hunt et al. 1980), EuroQol (EQ-5D) (The EuroQol
Group. 1990), the Medical Outcome Study 36-Item Short Form Health Survey (MOS SF-
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36) (Ware et al. 1992) and the RAND 36-Item Health Survey 1.0 (RAND-36) (Hays et al.
1993) have been most widely used in studies concerning heath-related QOL (HR-QOL) in
patients with critical illness in general (Niskanen et al. 1999; Eddleston et al. 2000;
Flaatten and Kvåle 2001; García Lizana et al. 2003; Cuthbertson et al. 2004; Graf et al.
2005; Kaarlola et al. 2006; Hofhuis et al. 2007) and specifically with severe sepsis
(Heyland et al. 2000; Weycker et al. 2003; Granja et al. 2004; Korošec Jagodi? et al. 2006).
NHP, MOS SF-36 and RAND-36 are generic health profile measures. Health profiles
provide  various  outcome  scores  on  different  QOL  domains.  They  allow  assessment  of
different conditions or treatments on the whole profile or one specific QOL domain. NHP
comprises 6 domains: energy level, emotional reactions, physical mobility, pain, social
isolation and sleep (Hunt et al. 1980). MOS SF-36 comprises 8 domains: physical
functioning, bodily pain, role limitations due to physical problems, role limitations due to
emotional problems, general mental health, social functioning, energy/fatigue, and general
health perceptions (Ware and Sherbourne 1992). RAND-36 actually includes the same
domains as those in the SF-36, but the scoring algorithm is different from that of the SF-36
(Hays et al. 1993).
Generic preference-based measures express the subjective health status with one health
index score. The index score is a single number, which is usually a continuum from perfect
health to worst outcome (1-0). The index score can be used in cost-utility analyses to
calculate quality-adjusted life-years (QALY) (Torrance et al. 1989). EQ-5D is a generic
preference-based instrument, which comprises 5 domains: mobility, self care, usual
activities, anxiety and/or depression and bodily pain (The EuroQol Group 1990). In
addition, it also includes a visual analogue scale (VAS) on the current health state.
MOS SF-36 and EQ-5D have been evaluated for reliability and validity in various studies
(Brazier et al. 1993; van Agt 1994; Chrispin et al. 1997). None of above mentioned four
instruments has been found superior to the others (Essink-Bot et al. 1997). However, in
critical care setting, SF-36 and EQ-5D are recommended by the 2002 Brussels Roundtable
(Angus et al. 2003). SF-36 serves as a comprehensive health profile measure and EQ-5D
with its single number health index can be used in QOL assessment and in cost-utility
analyses. Relatives or next of kin are able to answer reliably on QOL measures on behalf of
the patients (Rogers et al. 1997; Hofhuis et al. 2003).
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QOL before critical illness has been evaluated in some studies, and poor QOL has been
correlated with poorer outcome (Cuthbertson et al. 2005). Quality of life before intensive
care admission may even be equal to APACHE II score in predicting outcome (Hofhuis et
al. 2007). Severe sepsis is associated with organ failures, from which surviving patients
may recover slowly or have some residual dysfunction. Patients with ARDS (Angus et al.
2001 b) and severe acute respiratory syndrome (SARS) (Tansey et al. 2007) have exhibited
reduced QOL after one year of critical illness. The ARDS Study excluded septic patients.
Acute renal failure has a clear impact on deteriorating QOL and reducing long term
outcomes (Åhlström et al. 2005). While the QOL measured by EQ-5D is reduced after
major trauma and severe sepsis, there are no differences between the groups after two years
(Korošec Jagodi? et al. 2006).
Quality-adjusted life year and cost of treatment
A quality-adjusted life year (QALY) comprises length of life and quality of life. The
concept of QALY enables comparisons of the efficacies of different treatments and
calculations of costs per one QALY (Torrance et al. 1989; Kerridge et al. 1995). Cost-
effectiveness analysis measures the benefits of treatments in terms of the number of years
of lives saved. Cost-utility analysis measures treatments using a number of QALYs as a
unit of efficacy (Anonymous 2002). In intensive care medicine, the generally accepted cost
for one life year gained or for one QALY has been $50,000 (Talmor et al. 2006). Examples
of the cost per one QALY in different treatments are presented in Table 8.
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Table 8. Cost per one QALY in different treatments.
Reference Treatment Cost per 1 QALY
Añón et al. 1999 Respiratory failure in patients with
COPD and oxygen therapy and
mechanical ventilation
$26 300-$44 600
Mayer et al. 2000 Patients hospitalized for stroke with
mechanical ventilation
$174 200
Hamel et al. 2000 Acute respiratory failure (pneumonia
or ARDS) with mechanical ventilation
$29 000-$110 000
Sznajder et al. 2001 Intensive care treatment in general $4 100
CDC Diabetes Cost-
effectiveness Group 2002
Reduction of type II complications
-with intensive glycemic control
-with intensified hypertension control
-with reduction in serum cholesterol
level with pravastatin
$41 400
$2000
$51 900
Manns et al. 2002 Severe sepsis with activated protein C
-all patients
-APACHE II >25
-APACHE II <25
$46 600
$32 900
$958 400
Angus et al. 2003 b Severe sepsis with activated protein C $48 800
Fowler et al. 2003 Severe sepsis with activated protein C
APACHE II >25
APACHE II <25
$13 500
$403 000
Graf et al. 2005 Intensive care treatment in medical
ICU
$21 900
Green et al. 2006 Severe sepsis with activated protein C £8200
Ridley et al. 2007 Intensive care treatment in general £7000
Dhainaut et al. 2007 Severe sepsis with activated protein C 33 800 €
Graf et al. 2008 Cardiac arrest with cardiopulmonary
resuscitation
11 600 €
Talmor et al. 2008 Integrated sepsis protocol for severe
sepsis
$16 300
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3 AIMS OF THE STUDY
The  objective  of  this  study  was  to  evaluate  the  incidence,  clinical  course  and  short-  and
long-term outcomes of severe sepsis in adult patients treated in intensive care. The specific
aims were
1. To determine the incidence, associated organ dysfunctions and outcome of severe
sepsis in the adult Finnish population and to evaluate the compliance with
treatment guidelines in clinical practice (Study I).
2. To study the predictive value of high mobility group box-1 protein (HMGB1) and
hospital mortality in adult patients with severe sepsis and to evaluate the relation of
HMGB1 to severity of illness and development and type of organ dysfunction
(Study II).
3. To evaluate the relationship between vascular endothelial growth factor (VEGF)
and organ dysfunction and the value of VEGF in the prediction of hospital
mortality (Study III).
4. To determine long-term survival and quality of life (QOL) after severe sepsis using
a generic EuroQol (EQ-5D) questionnaire and to calculate quality-adjusted life-
years (QALYs) and costs per QALY for this patient group (Study IV).
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4 PATIENTS AND METHODS
4.1. PATIENTS
Four-hundred seventy patients were included in the Finnsepsis Study in 24 different ICUs
in 21 hospitals within a 4-month period. Consent was waived for collecting the severe
sepsis data but consent for the use of laboratory samples (for Studies II and III) was needed
within the first 24 hours and for quality of life (QOL) assessment (for Study IV) in the first
week after study entry. All patients participated in Study I and 250/470 patients
participated in Studies II-III. Samples for Study II were not available for analysis in 3
patients and the final number of patients in study II was 247. In Study IV, 252/470 patients
with consents participated in QOL assessment before severe sepsis and 156 patients
participated in QOL assessment after severe sepsis. The flowchart of included patients in
Studies I-IV is presented in Figure 5.
Figure 5. The flowchart of inclusion in studies I-IV.
4500 consecutive adult patients in 24 ICUs in Finland 1.11.2004-28.2.2005
470 adult patients with severe sepsis
according to ACCP/SCCM Consensus Criteria
470 patients with
472 septic episodes
(Study I)
250 patients with
consent for
laboratory samples
(Studies II, III)
252 patients with
consent for QOL
assessment with EQ-
5D (Study IV)
156 surviving patients
for QOL assessment
with EQ-5D after severe
sepsis (Study IV)
98 patients for two QOL
assessments with EQ-5D
(Study IV)
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In addition, 30 healthy individuals in Study II and 10 in Study III served as a control
group. Healthy individuals were hospital employees. The demographic data of the patients
in Studies I-IV are presented in Table 9.
Table 9. The demographic data of study patients.
Study I Study II Study III Study IV
Patient N 470 247 250 156
Male N (%) 315 (67) 171 (69.2) 172 (68.8) 114 (73.1)
Age, mean (SD) 59.6 (15.2) 59.3 (15.6) 59.4 (15.6) 58.6 (15.8)
APACHE II mean (SD) 24.1 (9.1) 23.8 (9.1) 23.8 (9.1) 22.3 (7.7)
SAPS II mean (SD) 44.8 (16.9) 43.5 (16.9) 43.5 (16.8) 41.1 (14.3)
SOFA at 24h, mean (SD) 8.4 (3.6) 10.9 (4.3) 10.9 (4.3) 8.2 (3.2)
Post-operative N (%) 136 (29) 65 (26.3) 65 (26.0) 41 (26.3)
ICU mortality N (%) 73 (15.5) 33(13.4) 33(13.2
Hospital mortality N (%) 133 (28.3) 65 (26.3) 66 (26.4)
4.2 METHODS
Study designs
Study I. Study I was a prospective observational cohort study. The purpose of the study
was to determine the incidence, associated organ failures and outcome on severe sepsis in
adult Finnish population. We also were interested to evaluate how some recommended
treatment guidelines in severe sepsis were applied. All consecutive ICU admission
episodes (4500) were screened for severe sepsis in a 4-month period (from 1 November
2004 to 28 February 2005). Severe sepsis was diagnosed according to ACCP/SCCM
Consensus Criteria (Bone et al. 1992). These criteria were fulfilled in 470 patients and all
these  patients  were  included  in  the  first  study.  Study  entry  was  the  time  when  all  three
criteria were met. If the patient had more than one severe sepsis episode from the same
source, only the first period was taken for severe sepsis incidence, treatment and outcome
analysis,  but  organ  dysfunctions  were  assessed  for  all  ICU days.  If  the  patient  had  more
than one severe sepsis episode from different sources, all periods were included in all
analyses except mortality. Eleven hospitals screened patients with antibiotic treatment for
severe sepsis on the wards on 4 separate predetermined screening days. Demographic data
and severity of illness scoring systems such as Simplified Acute Physiology Score (SAPS)
II score (Le Gall et al. 1993) and Acute Physiology and Chronic Health Evaluation
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(APACHE) II score (Knaus et al. 1985) were recorded. Haemodynamic data were collected
in the first 24 hours. Data concerning blood cultures, source of infection and use of
antimicrobial treatment were collected and the severity of organ dysfunction was assessed
daily by Sequential Organ Failure Assessment (SOFA) score (Vincent et al. 1998).
Adjuvant treatments, e.g. vasoactive and ventilator therapies and renal replacement
therapies were recorded, as well as the use of rhAPC and low-dose hydrocortisone. Length
of stay (LOS) in ICU and hospital  and ICU and hospital  mortalities were assessed. One-
year mortality data was obtained from Statistics Finland.
Study II. Study II was a substudy of the main study, where high mobility group box 1
protein (HMGB1) was analysed. HMGB1 was studied as a biomarker for severe sepsis and
severity  of  organ  failure  and  its  usefulness  in  outcome  was  tested.  Serum  samples  were
analysed by semi-quantitative Western immunoblotting (WB) analysis in 247 patients in
the first 24 hours and in 210 patients 72 hours later. The results were confirmed by
enzyme-linked immunosorbent assay (ELISA) in 170 randomly selected patients. Blood
samples from 10 healthy volunteers were analysed as controls with both methods.
Study III. Study III was a substudy of the main study, where vascular endothelial growth
factor  (VEGF)  was  tested  as  a  biomarker  for  severity  of  illness,  organ  dysfunction  and
outcome. Serum samples were analysed by ELISA in 250 patients in the first 24 hours and
215 patients after 72 hours. Blood samples from 30 healthy volunteers were analysed as
controls.
Study IV. In the fourth study the purpose was to ascertain two-year survival and health-
related quality of life (HR-QOL) in Finnsepsis Study patients. A generic EuroQol (EQ-5D)
(The EuroQol Group 1990) instrument was used for QOL assessment. QOL before critical
illness was assessed in 252 patients (54%) and the measurement was repeated in a median
of 17 months after severe sepsis. One-hundred and fifty-six patients (58%) responded the
second measure and of those 98 patients (63%) had also participated in the first measure.
Quality-adjusted  life-years  (QALY)  and  cost  per  QALY  were  also  estimated  for  non-
respondents. The QOL data of the respondents were assumed to be comparable for the
non-respondents, and thus the mean EQ-5D data of age- and gender-matched respondents
were used for QALY assessment in non-respondents. The mean cost for one QALY was
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calculated by using the mean ICU and the hospital cost of the study patients and dividing
the sum by acquired QALYs gained.
4.3 SCORING METHODS FOR THE SEVERITY OF ILLNESS
Severity  of  acute  illness  was  assessed  using  the  Acute  Physiology  and  Chronic  Health
Evaluation (APACHE) II score (Knaus et al. 1985) and Simplified Acute Physiology Score
(SAPS)  II  (Le  Gall  et  al.  1993),  which  were  calculated  in  the  first  24  hours  at  ICU
admission. Organ dysfunction or failure was assessed daily using Sequential Organ Failure
Assessment (SOFA) scores (Vincent et al. 1998). SOFA scores were calculated in the first
24 hours at ICU admission (SOFA at 24 h) and thereafter daily after study inclusion using
the poorest values during previous 24 hours. Missing organ specific SOFA score was not
replaced and the score was assumed to be zero. Maximum SOFA scores (SOFAmax)
(Moreno et al. 1999) were used to indicate the worst grade of sepsis-related organ
dysfunction. SOFA score 1-2 was graded as organ dysfunction and SOFA score 3-4 as
organ failure.
4.4 LABORATORY ASSAYS
Blood samples (II and III). Arterial blood samples for HMGB1 and VEGF analyses were
drawn after informed consent within 24 hours of the study entry (day 0) and 72 hours
thereafter. Blood for serum samples was collected in glass vacuum tubes (BD Vacutainer
369032) and the samples were prepared within 60 minutes of sampling. More specifically,
after 30-45 minutes of serum separation at room temperature the samples were centrifuged
at 3100 rpm (~1500 G) for 15 minutes. The samples were stored at –70ºC and transferred
from local hospitals to Helsinki University Hospital for storage and subsequent analyses.
HMGB1 analysis (II). In the Study II, HMGB1 concentrations were first measured by
Western immunoblotting (WB). Control samples were drawn from 10 healthy volunteers.
Because we failed to obtain a pure HMGB1 control, a pooled serum sample was used as an
inter-assay (inter-gel) control for the semi-quantification of HMGB1 levels in serum. The
HMGB1 signal on each gel was 'normalized' against the pooled serum sample from healthy
volunteers. The HMGB1 signal from the individual healthy volunteers (controls) was
similarly normalised against the pooled samples. Arbitrary units of HMGB1 activity (%)
on the gels were reported and used for statistical analyses. After a commercial enzyme-
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linked immunosorbent assay (HMGB1 ELISA Kit II; Shino-Test Corporation, Kanagawa,
Japan) became available, the blood samples of 10 healthy controls and day 0 samples of a
randomly generated subgroup of patients (N=170) were re-analysed by ELISA. Analyses
were measured in the University of Kuopio.
VEGF analysis (III). In the third study, VEGF was analysed by ELISA. Control samples
were drawn from 30 healthy volunteers. VEGF concentrations in sera were measured in
duplicate for each sample using a commercial enzyme-linked immunosorbent assay kit
(Quantikine®, R&D Systems; Minneapolis, MN) that recognizes the soluble isoforms
(VEGF121 and VEGF165). Analyses were measured in the University of Kuopio.
4.5 INTERVENTIONS
Patients were treated according to general accepted guidelines and protocols without
special therapeutic interventions except blood sampling and QOL assessment (EQ-5D)
after consent.
4.6 DATA COLLECTION
Data were collected daily at the participating hospitals by local study nurses and
investigators. All data were transferred and stored via the Internet in the Finnish Intensive
Care Quality Consortium (Intensium Ltd., Kuopio) database.
Data management. All data were collected to the internet based database. Every sixth
patient  was  rechecked  for  inclusion  criteria  at  study  entry  and  survival  status  at  hospital
discharge. In this recheck, each patient fulfilled the inclusion criteria. One ICU survivor
was registered as non-survivor, and this was corrected. One year mortality data was
obtained from Statistics Finland.
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4.7 OUTCOME MEASURES
Mortality (I, II, III, IV)
Short term mortality (I, II, III) comprised ICU and hospital mortality. The data were
obtained from the hospital records in the participating hospitals.
Long term mortality (I, IV) comprised one-year mortality and two-year mortality. The data
was obtained from Statistics Finland in May 2006 and in May 2007.
Quality of life (QOL) (IV)
Quality of life was assessed using generic, utility and preference-based EuroQol (EQ-5D)
instrument (The EuroQol group 1990). The EQ-5D measure consists of five different
domains: mobility (MO), self-care (SC), usual activities (UA), pain/disorder (PD), and
anxiety/depression (AD). Respondents were asked to choose the best suitable option from
three alternatives [no (=1), moderate (=2), or severe (=3) problems]. Five chosen options
created a serial number, from which one summary index (EQ sum index) was calculated.
All  dimensions  had  the  same  weight  only  in  the  best  category,  worse  categories  had
different  values  depending  on  dimension.  We  used  general  coefficients  and  reference
values in Finnish population (Ohinmaa and Sintonen 1996). In addition, the EQ-5D
instrument also comprised a 20-cm visual analogue scale, EQ VAS. Respondents are asked
to indicate their present health state by this scale, ranging from “0” (worst imaginable
health state) to “100” (best imaginable health state). EQ-5D domains, options and VAS are
presented in Table 10.
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Table 10. EQ-5D questionnaire.
By placing a tick in one box in each group below, please indicate which statements best describe your own
health state today
Mobility
I have no problems in walking about r
I have some problems in walking about r
I am confined to bed r
Self-Care
I have no problems with self-care r
I have some problems washing and dressing myself r
I am unable to wash or dress myself r
Usual activities (e.g. work, study, housework, family or leisure activities)
I have no problems with performing my usual activities r
I have some problems with performing my usual activities r
I am unable to perform my usual activities r
Pain/Discomfort
I have no pain or discomfort r
I have moderate pain or discomfort r
I have extreme pain or discomfort r
Anxiety/Depression
I am not anxious or depressed r
I am moderately anxious or depressed r
I am extremely anxious or depressed r
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To help people say how good or bad a health state is, we have
drawn a scale (rather like a thermometer) on which the best
state you can imagine is marked 100 and the worst state you
can imagine is marked 0.
We would like you to indicate on this scale how good or bad
your own health is today, in your opinion. Please do this by
drawing a line from the box below to whichever point on the scale
100
9  0
8  0
7  0
6  0
5  0
4  0
3  0
2  0
1  0
0
Your own
health state
today
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Quality-adjusted life year (QALY) (IV)
A quality-adjusted life year (QALY) comprises the length of life (the number of years of
lives saved) and quality of life. Patients' QALY units were calculated at the end of the first
quarter of the year 2007 by multiplying the time (years) the patient survived after hospital
discharge  by  the  value  of  the  patient's  EQ  sum  index.  QALY  units  for  the  patients  still
alive at that time point were calculated using the expected life years of the age- and
gender-adjusted Finnish population in the year 2005. QALY units were also estimated for
non-respondents and thus for all Finnsepsis patients. The mean EQ5D data of age- and
gender-matched respondents were used for estimating QALY of non-responders. This was
based on the assumption that the QOL data of the respondents was comparable to the data
of the non-responders.
If the patient died during the same hospital stay, QALY was defined as zero. Two
examples of QALY calculation are shown: The first patient lived 0.9 years after hospital
discharge and her measured EQ sum was 0.63 (EQsum index/100). The calculated QALY
will be 0.9 x 0.63 = 0.57. A second patient (male, 41 years) was alive in March 2007. His
EQ-sum was 0.69 (EQsum index/100) and his age- and gender-adjusted life expectancy of
general population is 36.3 years. QALY = 36.3 x 0.69 = 25.0.
4.8 STATISTICAL ANALYSES
Data are presented as absolute numbers (percentages), means (standard deviation, SD or
confidence interval, CI) or medians and interquartile range (25th to 75th percentiles,
interquartile range, IQR).
Statistical significance. A level of p<0.05 was considered statistically significant in all
tests in studies I, II and III. The level of p<0.01 was considered statistically significant in
all  tests  in  the  study  IV  due  to  multiple  comparisons.  All  statistical  analyses  were
performed using SPSS 12.1 (I), SPSS 14.0 (III) or SPSS 15.0 (II, IV) software (SPSS Inc,
Chicago, Illinois).
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Chi-Square test was used for categorical variables in all studies (I-IV).
Kaplan-Meier survival analysis was used to investigate one-year (I) and two-year (IV)
survival in different age groups in Studies I and IV.
Kruskall-Wallis test was used to compare continuously distributed data in more than two
independent populations. It was used to test the demographic and other data between
patients with first or second responses or with non–respondents in Study IV.
Mann-Whitney U-test was used compare continuously distributed data between two
independent populations. It was used to test patients´ demographic data (I-IV) and the
laboratory data between survivors and non-survivors in Studies II and III.
Receiver Operating Characteristic curve (ROC) analysis was  used  to determine the
prognostic accuracy of HMGB1 and VEGF on both time points. The receiver operating
characteristic (ROC) curves were constructed and the areas under the curve (AUC) were
calculated with 95% confidence intervals in Studies II and III.
Spearman's correlation was used to test the relations between the estimated time of onset
of sepsis and changes in HMGB1 (II) and VEGF concentrations (III).
Wilcoxon's signed matched pair test was used to compare differences between paired
groups. This test was used to analyse EQ-5D sum, EQ VAS, and corresponding reference
values in study IV.
4.9 ETHICAL ASPECTS
The ethics committees in each hospital approved the study protocol. The need for informed
consent was waived from collecting the data for severe sepsis (Study I), but consent was
needed for blood samples and quality of life assessments from patients or their next of kin
(Studies II, III, IV).
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5 RESULTS
5.1 INCIDENCE OF SEVERE SEPSIS (I)
During the 4-month study period, 4,500 adult patients were treated in 24 intensive care
units. Four-hundred and seventy patients suffered 472 episodes of severe sepsis. The
severe sepsis was community-acquired in 58% of cases and nosocomial in 39%. Blood
cultures were taken from 68% of patients and gram-positive bacteria were found in 59%
and gram-negative in 33% of positive blood cultures. Lung and intra-abdominal infections
were most common sources of severe sepsis, being responsible for 75% of all cases. The
incidence of severe sepsis requiring intensive care was calculated to be 0.38/1,000
adults/year (95% CI 0.34-0.41) in the population, which included 90.6% of Finnish adults.
The screening of 4843 adult patients with severe sepsis in the wards gave an additional
incidence of 0.31/1,000 adults. Consent for the use of laboratory samples (for Studies II
and III) was needed within the first 24 hours and for quality of life (QOL) assessment (for
Study IV) in the first week after study entry. Thus the estimated in-hospital incidence of
severe sepsis was 0.69/1,000.
5.2 ORGAN DYSFUNCTION AND TREATMENTS (I)
Respiratory failure (71.4%) and septic shock (77%) were the most frequent organ
dysfunctions. A majority of patients with severe sepsis (87%) needed mechanical
ventilation during their treatment period in ICU. Severe oxygenation impairment (SOFA
score > 3) was found in 71% of the patients. Seventy-seven per cent of patients had a
severe cardiovascular failure (SOFA score > 3) requiring vasoactive treatment. Acute renal
failure (SOFA score > 3) was found in 23% of patients. Half of those patients were treated
with renal replacement therapies.
Antibiotic treatment was ongoing at hospital admission in 20% of patients with community
acquired infection, but the median time for antibiotic treatment after hospital admission
was 7 hours (IQR 2.9-15.8) in this patient group. Patients with nosocomial infections were
already on antibiotic treatment in 70.5% of cases before severe sepsis was diagnosed.
RhAPC was administered only to 15 patients, although we identified at least 40 additional
patients with severe sepsis, multiple organ dysfunctions and disseminated intravascular
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coagulation (DIC), for whom rhAPC treatment could have been indicated. Low dose
corticosteroid  treatment  was  used  in  less  than  half  of  the  patients  with  septic  shock,  but
there was no difference in hospital mortality between these patients. Poorest compliance
was found with low tidal volume ventilation (15% in female patients).
5.3 IMPACT OF HMGB1 ON ORGAN DYSFUNCTION AND OUTCOME (II)
The mean APACHE II and SAPS II scores in the study patients were 24 (SD9) and 44
(SD17) respectively. The hospital mortality was 26%. Two-hundred and forty seven
samples were obtained at baseline (day=0) and 210 samples were taken 72 hours later. All
samples were analysed by Western immunoblotting (WB). A subgroup of 170 patients was
randomly selected for a reanalysis with ELISA in proportion to survivors (74%) and non-
survivors (26%). HMGB1 concentrations analysed by ELISA showed no correlation with
concentrations determined by WB (Spearman's rho 0.082, p=0.29). Corresponding
HMGB1 values for survivors and non-survivors measured with both methods are shown in
Figure 6. This data was not published in Study II.
Figure 6. HMGB1 levels measured with WB (HMGB1%) and ELISA (HMGB1 ng/ml).
The line represents the median concentration for healthy controls analysed by ELISA.
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Basic characteristics, disease severity, organ failure and mortality in the HMGB1 study
group were similar to other Finnsepsis patients. The median HMGB1 level on day 0 was
108% (IQR 98 and 119) and after 72 hours 107% (IQR 99 and 120). HMGB1 levels were
higher than the median HMGB1 level in healthy controls at both time points. The median
HMGB1 levels did not differ between survivors and non-survivors on day 0 or 72 hours
later. The reanalysis by ELISA confirmed these results. The HMGB1 levels in survivors,
non-survivors and healthy controls as measured with both methods are presented in Figure
7.
Figure 7. HMGB1 levels on day 0 in survivors, non-survivors and healthy controls
measured by WB or ELISA (Figures 2A and 2B combined from Study II).
HMGB1 levels and the severity of organ dysfunction (SOFAmax < 2) or organ failure
(SOFAmax  3-4)  did  not  correlate  with  the  day  0  measurement.  At  72  hours,  the  median
HMGB1 levels 103% (IQR 96 and 114) in patients with severe cardiovascular failure
(SOFAmax 4) were lower than at study entry (106%, IQR 97 and 117, p=0.001). Patients
with severe haematological failure (SOFA 3-4) also had lower HMGB1 concentrations at
72 h than on day 0 (103% [IQR 96 and 115] vs. 109% [IQR 97 and 118] p=0.032]. Levels
did not differ in milder dysfunctions or in other organ systems. Low HMGB1 levels were
associated with the severity of the total score of organ failure in patients with SOFAmax
score 14-24.
p=0.93
p=0.17
Western
immunobotting ELISA
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HMGB1 levels did not predict hospital mortality. ROC analyses with death as the outcome
showed areas under the curve (AUC) 0.51 and 0.56 (95% confidence limits 0.40-0.61 and
0.47-0.65 respectively) (Figure 8). The AUC in the HMGB1 ELISA subgroup was 0.57
(95% confidence limits 0.47 and 0.67) on day 0.
Figure 8. ROC  curve  for  HMGB1  in  predicting  hospital  mortality.  HMGB1_1  refers  to
levels on day 0 and HMGB1_2 refers to levels at 72 hours.
5.4 IMPACT OF VEGF ON ORGAN DYSFUNCTION AND OUTCOME (III)
The  mean  APACHE  II  and  SAPS  II  scores  in  the  study  patients  were  24  (SD9)  and  44
(SD17) respectively. Hospital mortality was 26%. Laboratory samples were obtained from
250 patients at study entry (day 0) and from 215 patients after 72 hours. The median VEGF
concentration was 260 pg/ml (IQR 126 and 459 pg/ml) in healthy volunteers. The median
VEGF concentration on day 0 (423 pg/ml [IQR 159 and 858 pg/ml]) and after 72 hours
(521 pg/ml [IQR 182 and 1092 pg/ml]) were higher in patients with severe sepsis than in
healthy volunteers (p=0.03 and p=0.003 respectively). The concentrations were lower in
non-survivors at both time points (p=0.012 and p=0.009 respectively). The VEGF
concentrations in survivors and non-survivors are presented in Figure 9.
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Figure 9. VEGF concentrations in survivors and non-survivors. (Figure 1 from Study III).
VEGF concentrations had influence on the severity of organ dysfunction. Patients with
severe renal, haematological or liver failure had decreased VEGF concentrations compared
to milder dysfunctions (p=<0.002, p=0.00 and p=<0.02 respectively). Cardiovascular or
respiratory dysfunctions were not associated with VEGF levels. Accordingly, VEGF
concentrations were associated with the severity of overall organ dysfunction. The patients
with SOFAmax score 14-24 had lower VEGF levels on both time points (165 pg/ml [IQR
54 and 466] and 208 pg/ml [IQR 52 and 339]) as compared to patients with lower
SOFAmax score. In patients with community-acquired severe sepsis, the hospital survivors
had increasing VEGF concentrations in contrast to hospital non-survivors with no change
or decreasing concentrations.
The overall VEGF concentrations did not predict hospital mortality. The ROC curves
(Figure 10) for VEGF levels showed no significant areas under the curve (AUC). The
AUC for day 0 VEGF was 0.58 (95% confidence limits 0.48 and 0.68) and for VEGF at 72
hours 0.63 (95% confidence limits 0.54 and 0.72).
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Figure 10. ROC curve for VEGF in predicting hospital mortality. VEGF_1 refers to
concentrations on day 0 and VEGF_2 refers to concentrations at 72 hours.
5.5 CORRELATION BETWEEN HMGB1, VEGF AND ORGAN
DYSFUNCTION
The  concentrations  between  HMGB1  and  VEGF  on  day  0  and  after  72  hours  correlated
poorly when HMGB1 was measured with WB (Spearman's rho 0.26 and 0.36
respectively). Nor was any correlation found between HMGB1 analysed by ELISA and
VEGF on the first day (Spearman's rho 0.055). Some survivors had high HMGB1 levels
and only moderately high VEGF concentrations, as shown in Figure 11.
Low VEGF concentrations associated with haematological failure (SOFA score 3-4) had
only moderate correlation with HMGB1 levels measured by WB (Spearman's rho 0.375).
In 40 patients with severe haematological failure, the HMGB1 concentration measured by
ELISA showed no correlation with VEGF concentrations (Spearman's rho -0.073). Forty-
nine patients with acute renal failure (SOFA score 3-4) and low VEGF concentrations had
only moderate correlation with HMGB1 levels on day 0 and at 72 hours (Spearman's rho
0.375 and 0.47 respectively), but no correlation with ELISA-measured HMGB1
(Spearman's rho 0.091).
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Figure 11. Correlation between VEGF and HMGB1 concentrations analysed by ELISA
(HMGB1 ng/ml) and WB (HMGB1%) on day 0.
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5.6 SHORT-TERM AND LONG-TERM OUTCOME (I, IV)
The ICU mortality was 15.5% and hospital mortality 28.3% in all Finnsepsis patients.
Hospital mortality was affected by the number of organ failures, as in patients with one
organ failure (SOFAmax score 3-4) the mortality was 11.5% but with three organ failures
mortality increased to 34.0%. Age had also a strong influence on outcome, as hospital
mortality was 40.0% in patients over 65 years of age and 20.4% in those under 65 years of
age. Long-term mortality was also higher in age groups over 55 years than those of
younger age groups (35.1% vs. 9.8%, p=<0.001). Treatment was withheld or withdrawn in
18% of patients during the treatment period in ICU. The cumulative one-year and two-year
mortalities were 40.9% and 44.9% respectively. The Kaplan-Meier survival curves for
one-year and two-year survival in different age groups are shown in Figures 12 and 13.
18-44
45-54
55-64
65-74
75-
Figure 12. Kaplan-Meier curves for one-year survival after severe sepsis in different age
groups. (Figure 3 from Study I).
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Figure 13. Kaplan-Meier curves for two-year survival after severe sepsis in different age
groups.
5.7 QUALITY OF LIFE, QUALITY-ADJUSTED LIFE YEARS AND COST OF
TREATMENT (IV)
Quality of life
Two-hundred and fifty-two patients participated in the quality of life assessment (53.6% of
patients)  (EQ  I).  The  majority  of  the  first  questionnaires  were  completed  by  next  of  kin
(61.9%). One hundred and fifty-six patients replied to the second (EQ II) questionnaire,
which was sent once to 269 survivors. The preadmission EQ sum and EQ VAS were both
lower than the age-and gender-adjusted references in the Finnish population. The median
response time for the second QOL assessment was 17 months (IQR 16-18) after hospital
discharge. The EQ sum and EQ VAS were lower in patients after severe sepsis than age-
and gender-adjusted references (Figure 14). The difference between the mean EQ sum and
corresponding reference value was 13 (SD 21; 95% CI, 9-16) and the difference between
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the mean EQ VAS and reference value was 8 (SD 19; 95% CI, 5-11). Ninety-eight patients
completed  both  EQ-5D  questionnaires.  EQ  sum  was  also  lower  after  severe  sepsis  than
before critical illness in this group of patients. EQ VAS did not differ from preadmission
values (Figure 15.
Figure 14. EQsum and VAS in 156 patients with EQ II responses.
Figure 15. EQsum index and EQ VAS in 98 patients who completed both questionnaires
(Figure 2 from Study IV).
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Quality-adjusted life years and cost of treatment
Mean QALYs gained were 15.2 (95% CI 13.8-16.7) in surviving patients and 10.9 (95%
CI 9.7-12.1) in all patients. QALYs in different age groups are presented in Figure 16. The
total costs of all study patients with severe sepsis were 10,973,768 euros and the total
estimated sum of acquired QALYs was 5131. The calculated cost for one QALY was
2,139 €. The costs for patients by age are presented in Figure 17. The costs varied between
individual patients and very expensive treatments were found in every age group under 75
years. The mean total cost for a surviving patient with severe sepsis was 32,563 €,
including mean costs of 22,915 € (70.4% of total) for intensive care and 9648 € for
treatment in ordinary wards. The mean estimated cost per QALY increased in older age
groups and varied from 325 € to 12,452 € (Figure 18).
Figure 16. Quality-adjusted life years (QALYs) after severe sepsis by age (Figure 3 from
Study IV).
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Figure 17. The cost of severe sepsis treatment of individual patients presented by age.
Figure 18. Cost-effectiveness of severe sepsis treatment (Figure 4 from Study IV).
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6 DISCUSSION
The incidence of severe sepsis is increasing as population ages and the aim to decrease the
morbidity and mortality associated with severe sepsis is a real challenge. The Finnsepsis
Study was a nationwide, prospective, multicentre study with coverage of nearly 90% of
Finnish adult population. Patients were identified with generally accepted and widely used
severe  sepsis  criteria  (Bone  et  al.  1992).  Data  for  the  Finnsepsis  Study  were  collected
locally by experienced ICU doctors and nurses and the reliability of the data was
confirmed by rechecking a part of the Finnsepsis data in every sixth patient while two
infectious disease specialists assessed the adequacy of administered antimicrobial
treatment. We analysed two markers of inflammation in a considerable number of patients
and the long-term outcome with QOL assessment was studied extensively. This study
likely improved the recognition, diagnosis and treatment of severe sepsis in Finland
because during the study period we specifically focused on this group of patients in Finnish
ICUs. At the same time, the Finnish treatment guidelines for severe sepsis in adults were
published (Finnish Anesthesiology Society 2005). Our results should be valid in an
unselected adult patient population with severe sepsis. The general challenges with clinical
studies are heterogeneous patient populations with various pathogens and indefinite severe
sepsis onset times. The current knowledge of effective treatments in severe sepsis is still
inconsistent and inadequate and under continuous re-evaluation.
Low incidence of severe sepsis in Finland
The actual incidence of severe sepsis and associated high mortality were realized
worldwide in the beginning of this millennium. The incidence found in different studies is
dependent on the population, time frame and methods. The incidence of severe sepsis has
varied from 0.5 to 3 cases per 1,000 inhabitants (Angus et al. 2001 a; Brun-Buisson et al.
2004). Prospective studies have been conducted usually in patients treated in intensive care
and retrospective studies have also included patients treated in hospital wards. Not
surprisingly, the incidence in retrospective studies (Angus et al. 2001 a; Martin et al. 2003)
has been even four times higher compared to prospective studies (Finfer et al. 2004 a;
Brun-Buisson et al. 2004). Before the Finnsepsis Study, the incidence of sepsis in the
Nordic  Countries  had  been  studied  only  retrospectively  in  Norway  and  the  estimated
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incidence was 0.48/1,000 inhabitants (Flaatten 2004). Our results are in accordance with
this retrospective incidence. The incidence was lower than previously published in
countries outside Scandinavia (Padkin et al. 2003; Finfer et al. 2004 a; van Gestel et al.
2004; Engel et al. 2007), but the proportion (10.5%) of severe sepsis in all ICU admissions
(472/4500) was comparable to the other countries. The low proportion of ICU-acquired
severe  sepsis  in  our  study  (9%)  may in  part  reflect  the  difficult  diagnosis  of  new severe
sepsis during the ICU stay than the true incidence (Ylipalosaari et al. 2006).
There may be several reasons for low incidence of severe sepsis in Finland and other
Nordic countries compared to the other regions in the world. First, as resistant microbes
are causing increasing number of septic infections (Annane et al. 2003), Finland has long
been a country with a low prevalence of methicillin resistant Staphylococcus aureus
(MRSA) or other resistant microbes. Previously over 99% of Staphylococcus aureus
bloodstream infections have been caused by methicillin sensitive strains (Lyytikäinen et al.
2005) but at present the number of MRSA cases continues to increase strongly (Kerttula et
al. 2007). At the time of the Finnsepsis study, no multidrug-resistant microbes causing
infections such as MRSA or vancomycin resistant enterococci were found. The antibiotic
treatment was considered adequate in 90.2% of patients at the time the positive blood
culture was taken. This effective antimicrobial treatment may also have an influence on the
moderate hospital mortality rates seen in the Finnsepsis Study. Secondly, 60% of patients
with community-acquired severe sepsis had previous physician contact and 20% of those
patients were on antibiotic treatment at the hospital admission. Finnish health care system
with health centres and general hospitals is easily accessible and it is likely that early
treatment of infections affects their severity. In the recently published SOAP study, a
considerable variation in the severe sepsis rates as compared to sepsis was shown between
different countries. (Vincent et al. 2006). In Scandinavia, 25% of septic patients had severe
sepsis compared to 45% in United Kingdom and Ireland.
Patients with severe sepsis are also treated in hospital wards. According to the Consensus
criteria (Bone et al. 1992), patients with mild, short-timing organ dysfunction may fulfil
the  definition.  In  general,  patients  with  severe  sepsis  should  be  treated  in  ICUs  or  high
dependency units. A few patients fulfilling the diagnosis of severe sepsis were treated on
the hospital wards of the participating hospitals during the Finnsepsis Study. Most of them
were not treated in ICUs because of severe comorbidities like incurable malignancies
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(unpublished data). Patients with severe sepsis are also treated in other than university or
central hospitals but their number was limited to a few patients in a month according to an
Internet-based query in regional hospitals without ICUs (unpublished data). Thus, it was
reasonable to assess the incidence of severe sepsis only in a critical care setting. In general,
prospective  studies  in  severe  sepsis  are  done  in  the  ICU patient  population  (Finfer  et  al.
2004 a; Engel et al. 2007).
Compliance to protocols and guidelines
The first Surviving Sepsis Campaign guidelines for management of severe sepsis and
septic shock were published in April in 2004, 6 months before the Finnsepsis Study started
(Dellinger et al. 2004). Many recommendations were based on studies published a few
years earlier (Bernard et al. 2001; van den Berghe et al. 2001; Rivers et al. 2001; Annane
et al. 2002). The adoption of some of these recommended treatments was incomplete
during the study. This is not surprising, since there are many studies concerning the
difficulty of implementing clinical guidelines into practice. Many of these reports assess
the use of low tidal volumes (Young et al. 2004; Rubenfeld et al. 2004) but the problem
applies to any recommendation or guideline (Cabana et al. 1999). However, after the
Finnsepsis Study, many of these above mentioned studies concerning treatment in
intensive care in general or specifically in patients with severe sepsis have been questioned
and re-evaluated. New studies failed to show benefit (Sprung et al. 2008) or revealed
harmful effects (Brunkhorst et al. 2008). This discrepancy has indeed confused the
clinician at the bedside.
At the time of our study, low dose corticosteroid treatment was recommended for septic
shock in general but it was administered to less than half (41.3%) of the eligible patients.
ACTH stimulation test was done on only a few patients (6.6%). Nowadays, stimulation test
is not recommended to identify those patients who should receive corticosteroids (Marik et
al. 2008). The compliance with the corticosteroid treatment might be considered only
moderate according to the guidelines obtained at that time.
In our study, the mortality did not differ in septic shock between patients with or without
low  dose  corticosteroid  treatment.  This  concurs  with  the  results  in  the  Corticus  Study
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showing no difference in mortality between patients with septic shock receiving
corticosteroids  or  placebo  (Sprung  et  al.  2008).  The  patients  in  the  Corticus  Study  were
less sick than in the first study to show benefit in septic shock (Annane et al. 2002). At
present, patients with vasopressor-resistant septic shock may be treated with low dose
corticosteroids (Marik et al. 2008). In our study, the number of patients with vasopressor-
resistant septic shock and low dose corticosteroid treatment were not definitely registered.
Treatment  with  activated  protein  C  was  given  to  one  third  of  the  patients  with  probable
indication according to Finnish recommendations published in 2003, which include DIC
and at least one other acute organ dysfunction (Pettilä et al. 2003). According to general
concept of the use of activated protein C in patients with at least two organ dysfunctions
and APACHE II score 25 or higher, activated protein C was given in 7% of these patients
in the Finnsepsis Study. This frequency can be considered rather low. However,
contraindications of the treatment such as recent surgery were not assessed. After our
study, the negative results using rhAPC in less severely ill patients were published
(Abraham et al. 2005) and a Cochrane review showed no evidence to advocate rhAPC in
patients with severe sepsis (Martí-Carvajal et al. 2008). New placebo-controlled trials with
rhAPC like PROWESS-SHOCK (Finfer et al. 2008) and APROCCHS
http://www.clinicaltrials. gov/ct2/ show/NCT00625209) will hopefully settle the
controversy surrounding this drug. Meanwhile, according to the Finnish guidelines rhAPC
may be administered to those patients with severe sepsis complicated by developing
MODS including DIC.
Tight glucose control was quickly and widely accepted also to be applied in patients with
severe sepsis after publication of the study results (van den Berghe et al. 2001). This was
the first study to show any mortality reduction after failures in specific sepsis treatment
trials (Abraham et al. 1998; Dhainaut et al. 1998). Treatment with insulin was considered
cheap and it was easily adoptable, because nurses at the bedside carried out the treatment.
In our study, blood glucose level was set at under 6.5 mmol/l in 41.5% and under 8 mmol/l
in 53.6% of patients. However, we did not analyse the glucose levels during the treatment.
The risk of hypoglycaemia with strict glucose control became soon evident. A recent meta-
analysis found no reduction in mortality in patients with critical illness but showed again
the increased risk of hypoglycaemia (Wiener et al. 2008). The results of the NICE-SUGAR
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study will be shown in 2009. We need to establish the best risk-to-benefit ratio in glucose
control.
At present, only few separate treatments have been found to affect outcome. The early and
proper antibiotic treatment is one example of a simple intervention that has been shown to
reduce mortality (Leibovici et al. 1998; Kumar et al. 2006; Varpula et al. 2007). Instead of
individual treatments, bundles consist of various goal-directed interventions and
procedures to be performed simultaneously or in certain time limits depending on the
disease process. The implementation and good compliance with treatment bundles and
protocols can decrease mortality in severe sepsis (Gao et al. 2005; Kortgen et al. 2006;
Ferrer et al. 2008).
Protocols even from successful trials showing mortality reduction are adopted slowly, if
ever (Kalhan et al. 2006; Umoh et al. 2008). It may be difficult to comply fully with strict
protocols and new knowledge has to be adapted at the bedside for individual patients. In
addition, protocols in randomised, prospective studies can lead to patients receiving a
completely different level of treatment than they would get without the study protocol. For
example, patients with ARDS might have been randomised to a group receiving higher
tidal ventilation than without the trial. This can make interpretation of the study difficult
and may even threaten the study safety (Deans et al. 2007).
The role of HMGB1 and VEGF in severe sepsis
In  our  patients,  high  HMGB1  levels  were  not  associated  with  different  types  of  organ
dysfunctions and unexpectedly, patients with the most severe organ failure had lower
HMGB1 concentrations than patients with milder organ dysfunctions. In addition, non-
survivors had lower serum VEGF concentrations than survivors and severe renal and
haematological failures were also associated with low VEGF. Neither HMGB1 levels nor
VEGF concentrations predicted mortality.
Our HMGB1 and VEGF measurements were studied in altogether 250 patients. Many
studies with divergent results have been conducted in studies with distinct difference in
size.  First  VEGF  measurements  in  septic  patients  were  done  in  18  (van  der  Flier  et  al.
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2005) and first HMGB1 measurements in 25 patients (Wang et al. 1999). Our patients with
HMGB1  and  VEGF  measurements  are  a  representative  group  of  patients  with  severe
sepsis.
The timing of laboratory samples to detect mediators with various half-lives is challenging.
Once elevated, no significant increase or decrease in HMGB1 levels has been found within
one week after onset of severe sepsis (Angus et al. 2007). This confirms that the two
samples taken from our patients within 72 hours are representative in measuring HMGB1.
A different time pattern may partly explain differences between the two small studies and
our study. The peak VEGF concentrations occurred in the first 24 hours and VEGF levels
remained elevated for up to several days (Yano et al. 2006. van der Flier et al. 2005). In our
study, more than half of our patients (56.7%) had further increasing VEGF concentrations
over  the  first  72  hours.  As  pointed  out  earlier,  the  severity  of  illness  and  the  exact  onset
time of severe sepsis vary in clinical studies and may have had an influence on the VEGF
levels. No adequate data exists to define which time interval should be used for the analysis
of VEGF and for this study, 3 days was used.
Experimental studies can determine the exact time for inducing sepsis e.g. with LPS
injection. In real life, the only exact time point we are aware of is the hospital admission
time. Conflicting results in different studies may reflect the fact that patients have been in
different phases of their sepsis or they present with different types of sepsis. Patients with
community acquired severe sepsis (Angus et al. 2007) probably differ from patients with
severe hospital acquired infections. Our patient population was mixed, with 58% of
patients having community-acquired infections.
We had some difficulties in measuring HMGB1 levels with WB which is a time
consuming and semi-quantitative method. We failed to obtain pure HMGB1 for a control
and we used somewhat arbitrary units to report the results. The WB method has limitations
because of possible cross-reaction with light chains of immunoglobulins (Sunden-Cullberg
et al. 2005) and indeed, in some of our healthy controls elevated HMGB1 levels were
measured. When the ELISA method for HMGB1 measurement became available, we
decided to re-analyse the samples of a subgroup of our patients and healthy controls. The
HMGB1 levels in healthy controls were very low, but could still be detected. HMGB1
levels measured with WB and HMGB1 concentrations measured with ELISA showed no
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correlation in an individual patient analysed by Spearman's correlation. However, the
primary results obtained by Western blotting were confirmed by ELISA concerning the
mortality and organ dysfunction. Some HMGB1 studies have been done with WB (Wang
et al. 1999; Angus et al. 2007) and others with ELISA (Gaïni et al. 2007; van Zoelen et al.
2007). These differences in methodology may be confounding and must be taken into
account when drawing comparisons between studies with different methodologies.
Short and long-term outcome
The ICU mortality in our study may be considered low compared to other studies reporting
mortalities of over 20% (Martin et al. 2003; Finfer et al. 2004 a) and the cumulative
hospital  mortality  of  28.3% is  similar  or  lower  compared  to  other  surveys  (Martin  et  al.
2003; Flaatten 2004). Age has been shown to be an independent risk factor for sepsis
mortality (Martin et al. 2006) and the effect of age was shown also in our study: the
patients over 65 years had twofold mortality compared to younger patients (40.5% vs.
20.4%). The number of failing organs affected strongly the mortality. The hospital
mortality in patients with at least two organ failures has been four-hold compared to
patients with only one organ failure (Guidet et al. 2005). The hospital mortality varied
between 38% and 71% in patients with at least two severe organ failures in our study.
However, the in-hospital increase in mortality over 10% is remarkable, even if the
approximate hospital mortality in severe sepsis has been about 30% (Angus et al. 2001 a;
Sundarajan et al. 2005). Restrictions of care such as withhold or withdraw of the treatment
was done in 18% of the patients. Severe co-morbidities or poor recovery from the
underlying disease have impact on hospital mortality. Nearly in half of those patients the
withhold  decision  was  done  at  the  discharge  from the  ICU thus  refusing  the  possible  re-
admission. The cumulative hospital mortality in our study was in concordance to the fact
that limitations of care in the ICU are the most powerful predictor of post-ICU mortality
(Azoulay et al. 2003). On the other hand, the hospital mortality was low (14.5%) for those
patients, whose treatment was not restricted in ICU or at discharge.
Most  patients  who  die  in  the  first  year  after  severe  sepsis  seems  to  die  in  the  first  two
months after hospital discharge. The cumulative one-year mortality in the Finnsepsis Study
was 40.9% and 2-year mortality was 1.5 times higher than the hospital mortality. Even if
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the survival was poor, the mortality was lower than previously published one-year
mortality of 51.4% (Weycker et al. 2003) and two-year mortality of 67% (Korošec Jagodi?
et al. 2006). In general, no excess mortality has been found after 2 years in patients
recovering from critical illness (Niskanen et al. 1996; Flaatten and Kvåle 2001). Former
sepsis trials have looked only the short term mortality as an endpoint (Bernard et al. 2001)
but forecoming trials should look at least 3-month or 6-month survival as their outcome.
To increase long term survival after severe sepsis, we should pay more attention to the
patient selection, post ICU care and rehabilititation.
Quality of life
The long-term survival with acceptable QOL should be one of the important outcomes after
critical illness (Angus et al. 2003 a). In our study, the surviving patients had lower QOL
than the age- and gender-adjusted population even 1.5 years after intensive care discharge.
However, the estimation of mean gained QALYs for a surviving patient was 15.2 years,
which can be considered a reasonable outcome after a life threatening disease.
QOL  was  already  lower  in  most  of  our  patients  before  the  episode  of  severe  sepsis
compared to the general population. Our gender- and age-adjusted reference values in
Finnish population for QOL assessment were measured over 10 years ago (Ohinmaa and
Sintonen 1996). Newer values are not available but this has hardly influenced our results.
QOL  before  critical  illness  has  been  evaluated  in  some  studies  and  poor  QOL  has  been
correlated with worse outcome (Cuthbertson et al. 2005. Hofhuis et al. 2007). No previous
studies exist concerning pre-illness QOL in patients with severe sepsis. Our results are in
accordance with other pre-illness QOL assessments, because before critical illness non-
survivors had lower EQ-5D index and VAS scores than survivors.
Quality of life has been studied increasingly among critical care in recent years, but most
studies have investigated critically ill patients in general. The number of septic patients has
been small or cannot be identified from the study population (Flaatten and Kvåle. 2001;
Graf et al. 2005; Kaarlola et al. 2006). In general, our results for QOL after severe sepsis
are  in  agreement  with  those  of  other  studies.  QOL  assessments  show  poorer  QOL  in
patients after severe sepsis compared to either controls like patients with trauma or to an
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age- and gender-adjusted general population (Heyland et al. 2000; Granja et al. 2004;
Korošec Jagodi? et al. 2006). Severe sepsis causes organ dysfunctions with a possible slow
recovery in surviving patients. Patients with acute respiratory distress syndrome have
impaired QOL one year after critical illness (Angus et al. 2001 b) and acute renal failure
has a strong impact on QOL and worsening the long term outcome (Åhlström et al. 2005).
Major trauma and severe sepsis both cause reduction of QOL, but no difference was found
between the groups after two years (Korošec Jagodi? et al. 2006).
Our QOL assessment was conducted at median 17 months after hospital discharge, which
we considered an adequate time period to recover from severe sepsis and its sequelae. In
other studies the time interval for QAL assessment has often been between 6 and 12
months (Niskanen et al. 1999; Granja et al. 2004; Hofhuis et al. 2007). However, the time
for  QOL  assessment  in  the  general  ICU  population  has  varied  from  the  time  of  hospital
discharge (Hofhuis et al. 2007) to as long as 6-12 years after ICU treatment (Flaatten and
Kvåle 2001; Kaarlola et al. 2003).
Earlier  clinical  studies  did  not  evaluate  QOL,  but  the  AT  III  study  was  one  of  the  first
clinical sepsis trials to publish quality of life results in study patients (Rublee et al. 2002).
At present, QOL assessment is recommended to be evaluated in all clinical trials (Angus et
al. 2003 a).
Assessment of QOL is more reliable using validated QOL instruments in large unselected
cohorts with extensive and reasonably long follow-up and with comparison to pre-ICU
baseline evaluation (Dowdy et al. 2005). We used in our patients the generic EQ-5D
measurement (The EuroQol Group 1990), which is recommended to be used in patients
with critical illness (Angus et al. 2003 a). EQ-5D is also suitable for cost utility analyses.
Our follow-up time was long enough, but the response rate in the second QOL assessment
(156 patients, 58% of the surviving patients) could have been higher. The response rate
often is reasonable low in this type of studies. Approximately 50-60% of surviving patients
have responded QOL assessment done by a telephone interview (Eddleston et al. 2000;
Granja et al. 2004). As we posted the questionnaire, the response rate may be considered
satisfactory.
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The mean cost for one QALY estimated in the Finnsepsis study definitely meets cost-
effectiveness  criteria.  Recently  published  estimates  of  costs  per  one  QALY  after  severe
sepsis have compared activated protein C to placebo and standard care and costs per
QALY vary from $7,800 to -$958, 000 (Manns et al. 2002; Fowler et al. 2003; Angus et al.
2003 b). In our patients, the costs per QALY increased by a factor of 40 with increasing
age from the youngest to the oldest patients. However, QALYs in the elderly patients are
not  equal  compared  to  younger  patients,  because  even  with  good  quality  of  life  QALYs
will  be  low  due  to  the  shorter  life  expectancy.  The  mean  costs  per  QALY  were  within
reasonable limits for all patients and our mean calculated costs per survivor and per QALY
seem to fall within the lower range of previously published data (Ridley et al. 2007;
Talmor et al. 2008).
The estimation of QALY is extremely sensitive to changes in distribution of age in treated
population, mortality rate and gained QOL. In our calculations, we used zero QALYs for
hospital non-survivors. The long-term QOL was measured by the validated measurement
and the mean age- and gender-matched values of respondents were used for the estimation
of QOL also for non-respondents. Even if these assumptions were made, we feel that our
calculation provides a reliable estimation. In addition, this method has been used in an
earlier study (Kaarlola et al. 2006). We also assumed for the QALY assessment that the
QOL of the study patients would be unchanged after 17 months, and that there would be no
excess mortality after 2 years, based on the previous Finnish study (Niskanen et al. 1996).
The costs of critical care were calculated by using the real costs in Finnish ICUs. The ICU
cost estimation is based on TISS point cost  based on all  patients treated in Finnish ICUs,
not only on patients with severe sepsis and thus we feel this method is reliable and
reproducible.  The  cost  for  a  treatment  period  in  hospital  ward  was  more  difficult  to
estimate, because hospitals have only average prices for ward treatment or the price is
based on a diagnosis-related group. As the majority of hospital costs (in average 70%) are
from intensive care, the relative impact of ward costs to final calculations was supposed to
be quite small. Social security, various insurance costs or rehabilitation costs were not
evaluated in this study.
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Limitations of the study
Our study has some limitations. Not all Finnish ICUs participated in our study, but because
90% of Finland's university and central hospitals participated, we consider it highly
representative. During a limited 4- month study period it is possible that seasonal changes
in the occurrence of diseases influence the observed incidence. However, no differences in
distribution of patients to different diagnostic categories have been found between the
seasons in Finland (Reinikainen et al. 2006). A small minority of patients with severe
sepsis may have been treated in small regional hospitals and on wards, which were not
included in the study. In addition, two ICUs treating transplant patients with
immunosuppression and susceptible to severe sepsis did not participate in the study. It
must be noted that the availability of beds in ICU wards may affect to both the severity of
disease during inclusion and the quality of care. In our study, we found only less than 1%
patients with severe sepsis who were treated outside ICU because of shortage of ICU beds.
The  blood  samples  for  HMGB1  and  VEGF  were  taken  only  at  two  time  points,  and
patients could have been at different phases in the course of their sepsis. However, onset of
sepsis  can  only  be  estimated  and  the  only  definite  time  point  is  the  time  of  the  hospital
admission. The first samples were taken, when patients met the criteria for severe sepsis or
septic shock and the second sample was taken 72 hours thereafter. We believe that 72 h
time  window  was  sufficient  to  detect  a  HMGB1  or  VEGF  response  if  present.  HMGB1
levels increase after 8 h in experimental endotoxin shock (Andersson et al. 2000) and stay
elevated at least one week (Sunden-Cullberg et al. 2005). The half life of VEGF is short
(Eppler et al. 2002), but studies have shown increased VEGF levels up to 29 days,
indicating sustained VEGF production in patients with severe sepsis (Yano et al. 2006).
The quality of life assessment in the first query comprised 53.6% of the Finnsepsis study
patients, and the second query was answered by only 56.1% of surviving patients. Two
large hospitals failed to require consents for QOL assessment, which was related to the
only moderate response rate. However, the demographic data did not differ between
respondents and non-respondents. Patients without response for the first questionnaire had
a higher ICU and hospital mortality. Therefore, the preadmission QOL could have been
overestimated. Those not responding to the second questionnaire were younger patients
with shorter ICU stays compared to patients with second responses. This may affect QOL,
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leading to an underestimation of QOL following the septic episode. The sample size for
coupled answers was quite small compared to all surviving patients (35%). Queries were
answered in part by patients' next of kin but relatives can reliably complete QOL
questionnaires on behalf of the patient (Hofhuis et al. 2003).
Clinical implications and future perspectives
Timing seems to be most important factor in the treatment and outcome in severe sepsis.
The onset of infection and body's inflammatory response should be identified as early as
possible,  but signs of severe sepsis may not be evident at  hospital  admission. At present,
we do not have biomarkers, which could early and reliably detect patients with progressive
severe sepsis or with increased risk of death. The early and goal-directed treatments have
changed our focus from intensive care to emergency room (Rivers et al. 2001) and on
wards (Ferrer et al. 2008). The right timing of adequate antimicrobial treatment is essential
for survival especially in septic shock (Kumar et al. 2006). The prompt administration of
broad-spectrum antimicrobial  treatment  has  the  equal  cost  as  the  delayed  administration,
but it can increase survival and is certainly cost effective.
The long term survival with the quality of life assessment has become most important
outcome after critical care. Ageing population increases the need for intensive care in the
future and we have to focus on treating those patients with acceptable long term outcome.
Quality of life assessment after intensive care with EuroQol-5D has been implemented in
Finnish Quality Consortium data in 2008.
Despite active investigation, evidence-based treatments and protocols are infrequent in
intensive care. Studies in intensive care in general have had conflicting results for example
in renal replacement therapies (Ronco et al. 2000. VA/NIH Acute Renal Failure Trial
Network 2008). It takes several years to complete a large, randomized, prospective study.
Groups of patients may differ from previous studies (Annane et al. 2002. Sprung et al.
2008) or other treatments may have changed during study years. Heterogeneous patient
population complicates the interpretation of study results in a specific patient group such
as severe sepsis. Future multi-centre studies should focus on specific patient groups to get
best applicable knowledge for clinical practice.
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The Finnish nationwide performance on the treatment of severe sepsis will be re-
investigated in the future Finnsepsis II study with the reproducible methodology of the first
study. This study may include the testing of new biomarkers or markers of gene
polymorphism giving a new insight into the recognition of patients with increased risk for
severe sepsis. In addition, a rapid pathogen regocnition for right-timed and adequate
treatment in increasing survival should be tested.
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7 CONCLUSIONS
Based on these studies the following conclusions can be drawn:
1. The incidence of ICU-treated severe sepsis in Finland is 0.38 per 1,000 of adult
population, which is lower than previously published in USA, Europe or Australia.
Respiratory failure requiring ventilatory support, cardiovascular failure and acute
renal failure were the most common severe organ dysfunctions associated with
severe sepsis. Prevailing recommended therapies were used for suitable patients in
only 15%-41% of cases. Cumulative ICU, hospital, and 1-year mortalities were
15.5%, 28.3% and 40.9%, respectively. The outcome of severe sepsis in Finland is
comparable to that reported for other countries.
2. Serum HMGB1 concentrations are moderately elevated in patients with severe
sepsis, but they do not differ between survivors and non-survivors and do not
predict organ dysfunction or hospital mortality.
3. Serum VEGF concentrations are elevated in patients with severe sepsis compared
to  healthy  controls.  However,  low  concentrations  are  associated  with  severe
haematological and renal dysfunctions. Although non-survivors have significantly
lower levels than patients with better outcome, VEGF concentrations do not predict
hospital mortality.
4. Cumulative two-year mortality after severe sepsis is high (44.9%) and QOL is
poorer after severe sepsis than in reference population as assessed by EQ-5D.
However, the estimated mean QALY (15.2 years) for the surviving patient is
reasonable and as the calculated cost for one QALY is only 2,139€, intensive care
in patients with severe sepsis is considered cost-effective.
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